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Summary
One-third of the world’s population is infected with the causative agent of 
tuberculosis, Mycobacterium tuberculosis. A fraction of infected individuals have an 
active form of the disease, while the remainder is able to control, but not eradicate the 
bacilli. The progression and outcome of the disease is dependent on precise 
interactions between the bacterium and its host, and the balance between the two 
organisms reflects thousands of years of co-evolution and adaptations. The host 
immune system recognises structural features of the bacilli, and immediately initiates 
responses upon pathogen entry. This does in turn lead to the development of highly 
specific immune responses that prime infected cells to become efficient 
mycobacterial killers. The bacterium on the other hand, produces molecules that 
modulate the responses in its own favour, and is therefore able to survive within the 
host cells for a prolonged time. In this thesis, our primary focus has been to 
investigate various aspects of the proteins produced by the bacterium. A broader 
knowledge in this field might contribute to the development of new vaccines, 
diagnostic markers, and drug targets, as well as providing increased understanding 
about the biology of this lethal pathogen.
In paper I, we determined the best algorithm for predicting mycobacterial proteins 
that are secreted via the general secretory pathway, which is responsible for secretion 
of a majority of secreted proteins. Proteins processed by this system harbour an N-
terminal signal peptide that is cleaved off as the protein is released on the exterior of 
the cell. The SignalP v3.0 hidden Markov model was found to be the best performing 
algorithm, and it identified the signal peptide of all proteins in a positive validation 
set, and did not generate any false positive results from a negative set. It also 
correctly identified the majority of the signal peptide cleavage sites. 
In paper II, we identified 30 proteins with predicted signal peptides that contrary to 
the prediction were observed to be uncleaved. These proteins were found to be 
enriched in the membrane fraction of the bacterium. A comparison of amino acid 
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sequences showed these uncleaved signal peptides to be similar to peptides known to 
be cleaved, but with some variations in the amino acid composition, particularly in 
the -3 and -5 positions relative to the cleavage site. Some of the proteins had a 
transmembrane domain spanning the predicted cleavage site, and which might 
interfere with the signal peptide processing. A combination of features probably 
explains why most of these proteins are not processed by the signal peptidase. It is 
possible that these uncleaved signal peptides act as hydrophobic anchors for their 
respective proteins, and cause them to be retained in the membrane.  
In paper III, we studied a long term (up to 17 months) course of infection with two 
BCG strains in mice, and investigated the in vivo expression of secreted and somatic 
mycobacterial proteins. BCG Pasteur is phylogenetically more distant from the 
original BCG strain than BCG Russia. According to the general belief that serial 
passages of a laboratory strain causes successive attenuation, BCG Pasteur should be 
more attenuated. However, in our mouse model, BCG Pasteur was more persistent 
and induced greater pathology than BCG Russia. The increased virulence of BCG 
Pasteur might be related to a higher expression of proteins with antioxidant 
properties, which make the bacilli more able to resist killing mechanisms of the host 
cells. At 2 and 3 months after infection we investigated the expression of 
mycobacterial antigens by immunohistochemistry using 7 different polyclonal rabbit 
antibodies. The staining patterns revealed strong staining, particularly in macrophage-
dominant areas, but also in lymphocyte-dominant areas and in bronchial associated 
lymphoid tissues. In addition, we observed scattered cells with high antigen load in 
the normal lung parenchyma. This likely reflects the ability of the bacilli to migrate 
from established foci to more distant cells and remain unnoticed by the host’s danger 
signalling system preventing it to alert other immune cells of the spreading infection. 
At the time point investigated, the immunohistochemical analyses revealed great 
similarities in protein expression between the BCG strains. 
In paper IV, we investigated the M. tuberculosis-expression and localisation of 
secreted and somatic proteins in human lungs and lymph node tissues. We found a 
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higher frequency of staining of the secreted proteins in loosely organised cell 
aggregates in the lungs, as compared to well-structured lymph node granulomas. In 
the latter, some major secreted proteins were only detected in the necrotic centres and 
not in the surrounding cells. Antibodies to the proteins of the antigen 85 complex 
gave generally low staining intensities, while anti-MPT64 produced strong staining of 
cells in all granulomas. Accumulation of proteins like MPT64 might eventually 
modulate immune responses to facilitate persistence of mycobacteria and 
pathogenesis of disease. Finally, staining with anti-Mce1A was found more 
frequently in organised granulomas, compared to regions without well-structured 
granulomas. This is in line with other studies that implicate a role for this 
mycobacterial protein in granuloma formation, and emphasises that both the host and 
the pathogen favour this structure.
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1. Introduction
1.1 Tuberculosis at a glance
Tuberculosis is caused by the bacterium Mycobacterium tuberculosis. This organism 
has coexisted with us humans since our origin, and is likely to have killed more of us 
than any other microbial pathogen. Despite extensive efforts to fight this disease 
during the last century, it remains one of our most ferocious killers. Around 1.7 
million people die from tuberculosis every year, which is a huge number in itself, but 
WHO has estimated that 2 billion people are infected with this pathogen (http://
www.who.int/topics/tuberculosis/en/). That is one-third of the world’s population; an 
enormous reservoir of the bacteria. This prevalence represents one of the greatest 
challenges in the fight against this disease.
Figure 1. Estimated TB incidence rate for 2009 (Centers for Disease Control and Prevention, 
Atlanta, USA)
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Diagnostic tools, treatment with drugs, vaccination programs, and improved living 
conditions and health care infrastructure, have almost eradicated the disease from the 
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industrialised world. The burden of epidemic disease now rests primarily on the 
developing world. It is tightly associated with poverty and poor living conditions, and 
tragically affects mostly young people in what should have been their most 
productive years. Twenty-two countries in Africa and Asia carries approximately 80% 
of the burden of this disease, with sub-Saharan Africa being one of the most 
intensively affected areas. Tuberculosis is also tragically linked to HIV, as coinfection 
with both pathological agents worsen the course of infection and outcome of both 
diseases (1).
Being infected with tuberculosis is not synonymous with clinical disease; the bacteria 
only cause active disease in an estimated 3-15% of those who are infected, the 
remainder have latent disease with no clinical signs of infection. Individuals with 
latent tuberculosis are able to control the disease, but not to the point of immediate 
eradication. Importantly, people with latent infection are not infectious, but they have 
a small chance of developing active disease later in life. The risk of reactivation is 
rapidly reduced as a function of time from the original infection, which strongly 
indicates that latency can be spontaneously cleared from the body (2). Active 
tuberculosis is partly characterised by symptoms like fever, a general malaise, and a 
long-lasting cough (3). The cough develops following inflammation and tissue 
necrosis of the lungs, and blood and sputum carries bacilli from the lung to the 
airways, and they are spread through droplet nuclei when the person coughs, sneezes, 
or talks. Worldwide, around 10 million people develop active tuberculosis every year. 
The greatest challenge for diagnosing tuberculosis is to distinguish between active- 
and latent tuberculosis. The sheer number of latently infected individuals makes it 
impossible to treat all cases and the focus of treatment is therefore patients with 
active and infectious form of the disease. Unfortunately, the current diagnostic tools 
are not optimised to specifically identify this stage, and clinicians primarily rely on 
clinical symptoms to identify contagious individuals. However, at this point the 
patient may already have infected several people in its near surroundings. The 
treatment of tuberculosis is cumbersome; the bacilli have a cell membrane that is 
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difficult to penetrate and they primarily reside inside host cells within dense cell 
structures called granulomas. Treatment therefore requires a long and strict course of 
multiple antibiotics. Failure to comply with the recommended treatment regimen is 
causing problems that might have a dramatic global impact; an emerging bacterial 
resistance to one or more of the available drugs presents a tough new challenge for 
controlling tuberculosis. The only available vaccine against tuberculosis, M. bovis 
BCG (Bacillus Calmette-Guérin, BCG), was made available in the 1920s, and has 
been widely used all over the world, in particular after World War II. This vaccine has  
undoubtedly saved many lives, but it also has its shortcomings; many adults living in 
areas with high prevalence of tuberculosis do not acquire complete protection from 
the disease, and can develop both latent and active tuberculosis despite prior 
vaccination with BCG.
1.2 The history of tuberculosis
The origin of the genus Mycobacterium has been hypothesised to be more than 150 
million years old (4), but the modern strains of M. tuberculosis seem to have arisen 
from a common ancestor around 20,000-25,000 years ago (5). These strains seem to 
have their origin in East Africa, and migrating humans from this area appear to have 
taken tuberculosis with them across to all parts of the globe. The disease probably 
didn’t reach epic proportions until humans started settling down in communities at 
permanent sites around 8000 BC, and investigations have revealed evidence of 
human tuberculosis in skeletons from one of the first villages with evidence of 
agriculture and domestication (6). Written accounts from India of the disease date 
back 3000 years, and it was recognised as a cause of death primarily in young adults 
in classical Greece (7). 
In Europe, the tuberculosis epidemic is likely to have started at the beginning of the 
seventeenth century. A combination of high population density and poor sanitary 
conditions in the largest cities provided the necessary condition for the spread of this 
pathogen, and it was considered inevitable that people that became sick with 
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tuberculosis would eventually die from the disease. Although tuberculosis is likely to 
have pre-existed in all continents, a disease of epidemic proportions seems to have 
spread from Europe to America, Asia and Africa by exploration and colonisation (8). 
At this time there was little knowledge about the disease. Although physicians 
described changes and tubercular structures in the lungs and in other organs, many 
believed the disease to be hereditary rather than infectious. In the nineteenth century, 
pathological studies of tuberculosis victims lay grounds for a better understanding of 
the disease. René Théophile Hyacinthe Laennec (1781-1826) described most of the 
physical signs of pulmonary tuberculosis, and invented terms to describe his findings 
that are still in use today (9). The infectious nature of the disease was proven by the 
French military surgeon Jean-Antoine Villemin (1827-1892) in 1865, when he 
inoculated liquid taken from a tuberculous cavity into a rabbit, and described 
extensive tuberculosis in the animal when it was sacrificed 3 months later (10).
It is, however, the work of Robert Koch (1843-1910), which he presented to the 
Berlin Physiological Society in 1882, that represents the biggest shift in the modern 
understanding of the etiological agent of tuberculosis (11). Koch developed methods 
for staining the bacteria, and was able to identify bacilli in tissues, both inside and 
outside host cells. Furthermore, he developed a special growth medium and was able 
to isolate the bacteria from animal and patient samples and grow them in his 
laboratory. He then infected a large number of guinea pigs and rabbits with the in 
vitro-cultivated bacteria, and established that these cultures were the source of 
tuberculosis. This stepwise method of showing that the bacteria isolated from 
diseased tissue is the actual cause of the disease, rather than an opportunistic 
organism accompanying an unrelated disease, was originally proposed by Friedrich 
Gustav Jakob Henle (1809-1885) in 1840, but was refined by his student Robert 
Koch and is now referred to as the Koch-Henle postulates (12). Koch also created a 
substance derived from his in vitro cultures he called tuberculin, and he hoped to use 
this to treat tuberculosis patients. Although it was quickly discredited as a treatment, 
the reaction it induced in people and animals with prior contact with tuberculosis, 
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revealed itself useful for diagnostic purposes (13). A paediatrician in Vienna called 
Clemens Freiherr von Pirquet (1874-1929) heard about Koch’s tuberculin in 1907, 
and used a vaccination lancet to introduce the substance subcutaneously, studied the 
subsequent swelling, and defined a cut-off for what he considered to be a positive 
response. He observed that some children had a positive reaction despite showing no 
clinical signs of tuberculosis, and coined the term latent tuberculosis to describe the 
phenomenon (14). In Norway, Johan Kloster (1901-1977) later modified this test by 
adding a drop of 1% adrenalin to make the reaction more prominent (15). An 
alternative method was introduced by Charles Mantoux (1877-1947) in 1908, who 
used a needle to inject tuberculin intracutaneously. In the 1930s, Florence Seibert 
(1897-1991) standardised production and isolation of proteins used for the test, and 
called it purified protein derivative (PPD). The suspension he created is very similar 
to the formulation that is in use today. 
During the time this pioneering work was ongoing, mortality rates caused by 
tuberculosis in the western world was gradually decreasing (16). Although the reason 
for this is not entirely clear, hypotheses put forward are improved social and living 
conditions, better nutrition, and the natural selection of a population more resistant to 
developing disease (17). The treatment regimens of the early days were to rest and eat 
well. Sanatoriums offered this, and they also served the purpose of isolating infected 
individuals and preventing them from spreading the bacteria to their families and 
other close contacts. Studies conducted at the time formally proved the benefit of this 
form of treatment; the cure rate was up to 20% higher for patients admitted to 
sanatoriums than for patients treated at home (18). That a simple treatment based on 
rest and a healthy and nutritious diet increased the chances of a positive outcome, 
underlines the fine balance in the tug of war between the bacilli and the human host 
during tuberculosis disease. A more drastic treatment introduced at the time was 
pulmonary collapse, primarily for the closure of cavities (10). This treatment was also 
recorded to have some degree of success in converting sputum positive patients to 
sputum negative.
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The colleagues Albert Calmette (1863-1933) and Camille Guérin (1872-1961) set out 
to develop a vaccine against tuberculosis in 1908, and their chosen method was to 
attenuate the causative agent of bovine tuberculosis, M. bovis, by subculturing this 
pathogen in a medium consisting of bile, glycerine and potato (19). After 11 years 
and 230 passages, they were confident that they had an attenuated organism that 
failed to give progressive tuberculosis when injected into guinea pigs, rabbits, cattle 
and horses. The first test on humans in 1921 was a success, and after 3 years the 
Pasteur institute in Lille began a mass production of the vaccine. By 1928, 114,000 
infants had been vaccinated without any serious complications recorded. Calmette 
and Guérin observed a fall in tuberculosis amongst the individuals that had been 
vaccinated with BCG, and within years the use of this vaccine spread to countries 
outside France. However, it was not until the World War II, which resulted in a large 
epidemic of tuberculosis, that BCG became administered on a massive scale 
worldwide.
The history of tuberculosis in man changed dramatically with the arrival of 
chemotherapies. In 1944 streptomycin was discovered, and a few months later it had 
been used to successfully treat a young woman with tuberculosis (10). Although the 
initial treatments were successful, it took between 2 and 3 months before 
improvements in clinical health and sputum bacteriology was observed. This 
prolonged use of a single antibiotic inevitably led to the development of antibiotic 
resistance. In the following years, isoniazid (1951) and rifamycins (1964) also 
became available, and it was the combined therapy using three antibiotics, all with a 
different mechanism of action, that eventually became the recommended therapeutic 
strategy. It reduced the course of treatment and largely overcame the problem with 
the development of drug-resistant bacteria. 
The BCG vaccine, diagnostic tools, and treatments described above are still in use 
today, and together with a much improved socioeconomic situation, they have 
contributed to almost complete eradication of tuberculosis from the majority of the 
populations of the Western world. However, in the developing world, where the 
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disease is truly endemic, it is necessary to radically improve the way we fight 
tuberculosis. In recent years, this absolute requirement has been recognised, and 
interest in research in the field has been generated alongside improved funding. An 
initiative lead by WHO, the Stop tuberculosis Partnership (http://www.stoptb.org/), 
has outlined a plan to halve tuberculosis prevalence and mortality by 2015, and to 
eliminate the disease as a public health problem by 2050. Because of such initiatives, 
the incidences of tuberculosis have slowly but gradually been falling. However, the 
development of resistant strains and the increase in mortality caused by co-infection 
with HIV, have highlighted the need for additional funding to refine and develop new 
tools to continue the fight against tuberculosis (20).
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2. The causative agent of tuberculosis
2.1 Mycobacterial taxonomy
Mycobacteria was first classified in 1896 when Lehmann and Neumann proposed the 
genus for the causative agents of tuberculosis and leprosy on the basis of their 
morphology and acid-alcohol fastness (21). It was placed in Mycobacteriaceae family 
(Mycobacterium is the only genus in this family), Actinomycetales order, and 
Actinomycetes class. Today, there are three main criteria for being included in the 
genus Mycobacterium: 1) acid-alcohol fastness (a feature that is exploited in acid-fast 
staining methods for diagnosis), 2) the presence of mycolic acids, and 3) a G+C 
content of the DNA of 61 to 71 mol% (22). The genus Mycobacterium is divided into 
two divisions: rapidly growing and slowly growing. This categorisation was initially 
based on their properties during in vivo culturing, but years later, 16S rRNA 
sequencing proved this division had a foundation in phylogenetic segregation (23). 
The slowly growing strains are generally associated with disease in human and 
animals, while rapidly growing strains are regarded as non-pathogenic. However, 
there are important exceptions to this correlation: for an immunocompromised 
individual almost all members of Mycobacterium can be pathogenic. To date, there 
are 120 recognised and proposed species that meet the standards for inclusion in the 
genus, and the vast majority is considered non-pathogenic.
Members of the Mycobacterium tuberculosis complex are the causative agents of 
tuberculosis, and form a tight cluster in taxonomical studies: Mycobacterium 
tuberculosis, Mycobacterium bovis (including the BCG vaccine strains, that was 
attenuated from a clinical isolate of M. bovis called “lait Nocard”), Mycobacterium 
africanum, Mycobacterium microti, Mycobacterium caprae, Mycobacterium canetti 
and Mycobacterium pinnipedii, which are all pathogenic for human and/or animals. 
The properties described in the next chapter are specific to the members of this 
Mycobacterium tuberculosis complex, primarily Mycobacterium tuberculosis.
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2.2 Mycobacterial characteristics
2.2.1 Historic observations
In 1880, after Robert Koch accepted the position as director of the bacteriological 
laboratory at the Imperial Health Office in Berlin, he immediately started to develop 
the tools required for bacteriological work, including staining methods, solid culture 
media, incubation boxes, experimental animal studies, and microscopy and 
microphotography (12). These methods allowed him to both cultivate the agent of 
tuberculosis, observe the bacterium inside and outside cells in animal specimens, and 
to document his findings. For M. tuberculosis, what he described was a slightly bent, 
rod-shaped cell, approximately 2-4 µm long and 0.2-0.5 µm wide. These bacteria are 
slow-growing, with a replication time of around 21-23 hours in human macrophages. 
Most mycobacterial species can grow on simple substrates, and optimal growth 
temperature can vary greatly. The exceptions are M. leprae and the closely related 
Mycobacterium lepromatosis, which causes a special form of diffuse lepromatous 
leprosy. M. leprae has till this day not been successfully cultivated in culture 
medium, and is therefore grown in armadillos when cultivated for scientific purposes. 
Mycobacteria are aerobic, and considered to be non-motile and non-sporulating. They 
are described as acid-fast, a feature that stems from its unique cell envelope. These 
bacilli have for a long time erroneously been thought to lack a true outer membrane, 
and they have therefore traditionally been considered Gram-positive, even if they do 
not retain the crystal violet stain well like other Gram-positive bacteria.
2.2.2 The unique cell envelope
The complex wax-rich cell envelope, which consists of a cytoplasmic membrane and 
a cell wall, is one of the distinguishing features of this organism. It makes up a very 
rigid structure, and function as a permeability barrier that plays a crucial role in 
survival under tough conditions and gives the bacteria intrinsic drug resistance (24). 
Mycolic acids account for 30% to 40% of the envelope. These are long fatty acids 
that are linked to peptidoglycan by an arabinogalactan polymer, which is a 
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polysaccharide composed of arabinose and galactose subunits. This acid-
arabinogalactan-peptidoglycan polymer is arranged to form a hydrophobic layer 
together with other lipids (25). The outer membrane of mycobacteria has been the 
subject of some controversy, where some have been sceptical to the existence of a 
‘true’ membrane and have instead argued that the structure was similar to that of 
Gram-positive bacteria. However, recent cryo-electron tomography and electron 
microscopy has revealed a bilayer structure of a true outer membrane. It is 
approximately 8 nm thick and morphologically symmetrical, which suggests that free 
lipids with heterogeneous head groups are distributed over both leaflets in the outer 
membrane (26,27).
Components of the cell envelope play an important role in mycobacterial virulence 
ranging from granuloma formation to inhibiting killing mechanisms of infected 
macrophages. A more detailed description will be given in chapter 5, which deals 
with the interaction between the pathogen and its host. The cell envelope differs 
between mycobacterial species, and it gives some of these species properties that are 
not found in others. An example of this is the ability to aggregate into structures 
known as cords, which has been linked to the lipid composition of the M. tuberculosis 
cell wall (28-32). The cord-formation has been linked to virulence, and underlines 
importance of the mycobacterial cell envelope for bacterial perseverance and 
virulence in the host.
2.2.3 The genome sequence
The complete genome of the laboratory reference strain M. tuberculosis H37Rv was 
published in 1998 (33), and since then, genome sequences from several other M. 
tuberculosis strains and species of mycobacteria have been published (34-39).
The genome of M. tuberculosis consists of approximately 4.5 million base pairs, 
making up a predicted 3995 genes (40). The G+C content is higher than most known 
bacterial species and averages at 65.6%. The areas of the genome that contain the two 
novel PE- and PPE gene families were found to have an even higher G+C ratio, and 
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an amino acid composition that differs from other mycobacterial proteins. Despite 
making up to 10% of the coding potential of the genome, the function of these genes 
is still unknown, although a role in pathogenesis and antigenic variation has been 
suggested (41). The basis for the lipid rich cell envelope can be traced back to the 
genome, where every known lipid and polyketide biosynthetic system has been 
identified, including enzymes that are typically found in mammals and plants. In fact, 
more potential lipid biosynthetic activities were identified than there are known 
metabolites, which suggests the existence of novel lipid and polyketide species that 
are yet to be found. Many genes seems to encode enzymes that are involved in fatty 
acid degradation, which could be linked to the degradation of lipids that are present in 
host membranes, and thus contribute to the energy metabolism of this intracellular 
pathogen (33).
The genome of M. tuberculosis has three types of repetitive sequences: duplicated 
genes and gene families, insertion sequence (IS) elements, and dispersed non-coding 
sequences. Gene duplication is a common feature of many organisms, but in M. 
tuberculosis the duplication of certain genes has lead to the presence of copies that 
are identical in sequence. Typically, extensive sequence divergence is more common 
after duplication events. The PE and PPE gene families are the dominant examples of 
duplication events producing near identical genes. There are 56 copies of IS elements 
that belong to 9 different families of genes, and they often appear in clusters. These 
elements are thought to be the targets of transposons, since insertions into these 
sequences will not disrupt essential genes and alter the function of the organism (42). 
However, with the exception of IS6110, most elements found in M. tuberculosis 
H37Rv appear to be stable and maintain a conserved location in the genome. Seven 
copies of repetitive sequences exist that are collectively known as the 13E12-family. 
They contain an open reading frame, that in some cases appear to require frame shift 
to produce a protein. In addition, there exists smaller repetitive sequences called 
mycobacterial interspersed repetitive unit (MIRU), variable number tandem repeats 
24
(VNTR), and exact tandem repeats. Many MIRUs are situated in between genes in 
operons, and therefore have the potential to encode peptides (43).
2.2.4 From genome to proteome
The output of genome-wide sequencing is a raw sequence of nucleic acids, and from 
this sequence the researchers try to accurately predict, or annotate, every gene this 
genome might contain. The value of a genome sequence, and the biological 
information it provides, is therefore only as good as its annotation. They will 
normally start by mapping the genome for known genes, repetitive elements, 
duplications, and so forth to get an overview over landmark features. To identify the 
genes, it is necessary to identify long open reading frames that starts with a start 
codon and terminate with a stop codon. The stop codon is unambiguous, but the 
alternative start codons, ATG, TTG, and GTG, also codes for the amino acids 
methionine, leucine, and valine, respectively. These might therefore appear at any 
place within the final protein, in which case a different start codon further upstream 
will be the actual start of the protein. Finding the true starting point is therefore 
essential for a correct gene annotation. Furthermore, open reading frames exist on 
both strands of the genome, and in some cases genes overlap on the opposite strand. 
Gene annotation is therefore a complex task, and luckily several software algorithms 
exist that can aid the prediction by detecting features based on motifs or other 
properties of the DNA. Alongside being analysed by prediction algorithms, the 
genome is compared to gene sequences from other species that already have been 
characterised. This comparison is particularly valuable for elucidating the function of 
each of the predicted proteins. The result is a division of proteins into the following 3 
broad categories: 1) proteins with great similarities to known proteins and that can be 
attributed precise functions, 2) proteins with similarities to known proteins, and 3) 
proteins that do not resemble any known proteins, often referred to as hypothetical 
proteins. The hardest task is to annotate genes that belong to the latter category. 
However, mistakes can be made even if a sequence shows great similarity to a 
previously annotated gene. For example, a pseudogene has lost its protein-coding 
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ability and has no function in the bacilli, yet it is highly similar to the original 
functional gene from which it is derived. When the genome of M. tuberculosis was 
first sequenced in 1998, around 40% of the genes were attributed precise functions, 
44% was found to have great similarity to known genes, while 16% did not resemble 
any known protein (44).
The annotated genome can further be subjected to in silico analyses. Software 
algorithms have been developed that use sequence information from proteins that 
have already been characterised, and which have been found to contain a specific 
property. The algorithms are “trained” on sequence information from several proteins 
that share the same feature, and they can subsequently predict the probability of this 
trait being present in new and less well-characterised proteins. Good examples of 
such prediction algorithms are computer programs used for identifying N-terminal 
signal peptides. These amino acid sequences are responsible for transporting proteins 
to the membrane, where they are processed by the general secretory system, and 
released on the exterior of the cell as the signal peptide is cleaved off (this is 
described in more detail in chapter 3.2.1). The algorithm can therefore both disclose 
the final destination of a protein, and reveal the mature protein sequence after 
removal of the signal sequence. The best of these algorithms can accurately identify 
signal sequences in many different eukaryotic and prokaryotic species (45), including 
M. tuberculosis (46). However, since such computational methods are developed 
from benchmark datasets consisting of pre-existing experimental data, there is no 
guarantee that the prediction is correct.  Only when experimental research verify such 
predictions can we be certain the organism actually expresses these proteins.
The study of proteins, often referred to as proteomics, predates genomic analyses, but 
traditionally the methods used were laborious and generated a relatively low-output 
relative to the effort. However, several important mycobacterial proteins were 
identified and described many years before the gene sequence was made available, 
making it possible to isolate and characterise several important antigens and to 
identify features that distinguish pathogenic from non-pathogenic mycobacterial 
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strains. These days the new and refined proteomic tools are used to both verify and 
correct gene annotations that were published following the sequencing of the M. 
tuberculosis genome. 
As mentioned above, genome annotation relies heavily on computational methods, 
which in turn are based on the fairly limited information gained from prior 
experimental research. Sequence comparisons are often made to unrelated organisms, 
and mistakes are commonly found in the available gene and protein databases. The 
vulnerability of such methods are exemplified by the sequencing and annotation of 
the genome of the lab strain M. tuberculosis H37Rv. The work was carried out in 
parallel by two separate institutions, the Pasteur Institute and the J. Craig Venter 
Institute, and the number of genes annotated by the two groups turned out to differ by 
12% (35,44). After the M. tuberculosis-genome sequence was made available, several 
proteomic studies sought to either verify, or correct, the annotations and predictions, 
and to identify proteins expressed from genes that has not been annotated at all 
(47-55). These studies were performed using mass spectrometry based methods that 
are both sensitive and allows large scale screenings (56). In 2008, de Souza and co-
workers performed a proteomic characterisation of M. tuberculosis H37Rv, and were 
able to conclude that the annotation from the Pasteur Institute was the most accurate 
annotation of the two (52).
This is not the only achievement of modern proteomics with regard to mycobacterial 
species. Mycobacterial proteins located within or attached to the membrane, or 
secreted into the environment, have important roles in pathogen-host interactions. 
They are therefore particularly interesting for the development of new vaccines, 
drugs, and diagnostic tools. Proteomic analysis of membrane fractions have 
extensively documented its protein content (53,57,58), and a thorough screening of 
culture filtrates have characterised a large amount of the proteins that are thought to 
be secreted (51,52,59). Other types of analyses have revealed several examples of 
post-translational modifications of mycobacterial proteins. These types of findings 
are important to better understand how the bacteria can regulate key pathways and 
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respond to signals from its environment. Prisic and co-workers recently identified 
301 proteins that were found to be phosphorylated under one or more external 
conditions such as nitric oxide stress, hypoxia, and in response to variable carbon 
sources (60). Phosphorylation and dephosphorylation activate or deactivate many 
proteins, and are important steps in many signal transduction pathways. Another type 
of modification, ubiquitination, is used to target proteins to proteasomal degradation. 
In 2008, the ubiquitin-like protein Rv2111c was described in M. tuberculosis, and this  
was the first time an ubiquitin-like system was described for a bacterial species (61). 
Subsequently, proteomic approaches have identified a total of 48 sites in 41 proteins 
as targets for this type of modification (62). Lipoproteins exported by the general 
secretory pathway become acetylated at the N-terminal cysteine, and several are also 
O-glycosylated close to the N-terminal end. Both modifications have been suggested 
to protect these lipoproteins from proteolytic cleavage before they reach their final 
destination. In M. tuberculosis, such modifications have been found for various 
lipoproteins including MPT83 (63) and SodC (64). The non-lipoprotein MPT32 
(Apa) (65) is known to be glycosylated, and is currently the only mycobacterial non-
lipoprotein where this type of modification has been described (66). There is 
evidence to suggest that post-translational modifications directly affect how the 
immune system recognises mycobacterial antigens. The heparin-binding 
hemaglutinin is exposed on the surface of the bacilli, and has been found to be 
methylated on several lysine residues (67). These methyl lysines are now believed to 
be part of the epitopes recognised by T-cells, and may be important for generating a 
specific immune response (68).
Another relatively new field within proteomics are quantitative studies that allow the 
description of the relative abundance of identified proteins. So far these methods have 
confirmed that many of the already well-established immunogens of mycobacteria 
are indeed highly expressed. The hope and promise of quantitative proteomics is to 
identify proteins with significant expression, but which so far have largely been 
overlooked. These proteins can be evaluated as candidates for vaccines, target 
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antigens in diagnostic tests, and drug targets. Furthermore, they may be involved in 
important biological activities of the bacteria, and are therefore interesting in their 
own right. A study that identified several proteins with relatively high expression was 
recently performed for M. leprae (69).
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3. Protein expression and localisation
3.1 Transcription and translation
Mycobacteria, like all prokaryotes, do not have a separate compartment, a nucleus, 
where DNA is located. Both transcription of DNA and translation into proteins 
therefore takes place in the bacterial cytoplasm. Since the bacterial genome is 
relatively streamlined, with no exons or introns that needs to be edited out before the 
mRNA can encode a functional protein, translation of mRNA can start before 
transcription has been completed. Transcription is carried out by a four-subunit RNA 
polymerase, and a transcription factor (in prokaryote often referred to as sigma 
factor) that enables this complex to recognise the promoter region that consist of a 
TATAAT and TTGACA sequence that are 10 bp and 35 bp upstream the start codon, 
respectively. Transcription factors bind directly to the promoter region of the genes 
they regulate, and function to either promote or block the binding of RNA 
polymerase. Their role is therefore to increase or decrease gene transcription. The 
transcription factor can be aided by other cofactors, but these do not have the capacity 
to bind DNA directly. When the polymerase binds to the promoter region, it starts 
transcribing the gene, and it generates an mRNA sequence that will be translated into 
a protein. An operon consists of several genes located close together, which are 
transcribed from the same promoter region, and thus controlled by the same 
transcription factors. Each gene in this region can have its own start- and stop-
codons, and a separate mRNA string for each gene is made. Sometimes the mRNA 
encodes more than one protein, in which case it is called polycistronic (as opposed to 
monocistronic) and an intercistronic region separates each gene on the single mRNA 
string. The chromosome can be transcribed on both strands of DNA, both 5’ to 3’ and 
3’ to 5’, and genes can therefore overlap by utilising the same genome sequence 
albeit in opposite directions. Genes can also overlap on the same strand, in which 
case there is an offset in the reading frame by 1 or 2 codons.
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Since expression of proteins can be controlled at the level of transcription, the 
activities of transcription factors are important for adapting to changes in the 
environment. The genome of M. tuberculosis have been found to contain a large 
number of putative transcription factors, including 12 sigma factors (33), and 
furthermore, microarray data has revealed shifts in transcription profiles when the 
bacteria encounter the hostile environment of the macrophage (70). This underlines 
the important roles of transcription factors and gene regulation for bacterial 
adaptation, survival and pathogenicity.
The polypeptide chain that emerges from the ribosome during translation consists of 
amino acids that differ in the chemical nature of their side chains. These side chains 
can react with various molecules already present in the cytoplasm, which can prevent 
formation of a stable and functional mature structure (71). To prevent this, 
polypeptides therefore often start folding before the protein has been completely 
translated (72). In addition, stabilising chaperons, like heat shock proteins, associate 
with the newly synthesised polypeptide during translation and aid the correct folding 
of the protein. Under normal conditions, heat shock proteins constitutes around 5% of 
somatic proteins, but under stressful conditions these proteins can represent up to 
15% of the prokaryotic cellular protein mass. Since the stress experienced by 
intracellular pathogens inside host cells cause an up-regulated production of heat 
shock proteins, they typically become important immunogens inducing strong 
humoral and cellular immune responses (73). 
Once synthesised, the protein can either remain intracellular or it can be transported 
to the membrane into which it can be inserted, or exported through and eventually 
released on the exterior of the cell. The latter two groups of proteins, membrane- and 
secreted proteins, are particularly important for host-pathogen interactions, and are 
frequently recognised by the host immune system. These proteins require a system 
for localising to sites where they will be further processed. As it turns out, many of 
these proteins are recognised and processed by the same system despite their 
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divergent destinies. It is the intrinsic properties of the individual protein that 
determine if it will be retained within the membrane or released on the outside.
3.2 Protein secretion mechanisms
Secretion mechanisms in M. tuberculosis consist of highly conserved systems, but 
more specialised systems also exist. Protein transport through the SecYEG-integral 
membrane complex, which involves the activity of Signal peptidase (SPase) I, is the 
core system in all domains of life. It is highly conserved and therefore called the 
general secretory pathway (74). The transport of lipoproteins through the twin-
arginine translocation (TAT) machinery seems to be conserved across prokaryotes 
(75). In addition, mycobacteria have a secretion system that is more specialised and 
unique to a limited number of prokaryotes. The ESX-1 secretion system seems to be 
functionally equivalent to the Type I-V secretion systems of some pathogenic Gram-
negative bacteria, which serve to transport proteins into the host cell and interfere 
with the host response to infection.
3.2.1 The general secretory pathway and signal peptides
The general secretory pathway secretes proteins that are “labelled” with an N-
terminal amino acids sequence, called the signal peptide. These signal peptides 
ensure the correct transport and post-processing of the protein. The N-terminal 
sequence interacts with a transport system that transfers the protein to a secretion 
system located on the cytoplasmic side of the cell envelope. At this site, the protein 
adapts to a structural confirmation that exposes a specific region of the signal peptide 
to an enzyme that cleaves the signal peptide from the protein. After the cleavage 
event, the protein becomes “mature”, and it can be released from the cell or contained 
within the membrane fraction. Typically, proteins that contain one or more 
transmembrane regions are retained in the membrane and perform their functions as 
part of the membrane structure, be it on the surface, on the cytoplasmic side, or 
within the membrane layers. 
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The protein complex involved in translocating proteins, the translocon, consists of 3 
proteins, SecY, SecE, and SecG (SecYEG) that forms a channel across the 
cytoplasmic membrane. Peripherally attached on the cytoplasmic side is the ATPase 
motor, SecA, which drives the translocation in an ATP-dependent manner. In 
addition, a protein complex called SecDF, and the protein YidC, associates transiently 
with the translocon, but their role in the translocation process in not clear. Soon after 
transcription the pre-protein, which still have an N-terminal signal sequence, is 
transported to the translocon. It first interacts with SecA that binds both to the signal 
peptide and the mature protein. Not all proteins require a signal peptide for this 
interaction, and appear to associate just as well when the signal peptide is impaired 
(76). The protein domain downstream of the signal peptide therefore seems to be the 
primary interaction partner with SecA.
Some proteins require the aid of molecules to keep them in an unfolded non-
aggregative state compatible with the translocation system. Signal recognition 
chaperons immediately bind to the peptide emerging from the ribosomal tunnel, and 
delivers the protein to the translocon via a membrane bound protein. Other proteins 
do not require the assistance of chaperons; they remain unfolded and can associate 
with the translocon independently. It is not understood why some proteins require 
assistance while others do not. For example, the chaperon SecB found in 
proteobacteria cannot distinguish between secreted and non-secreted proteins by its 
binding specificity. Furthermore, a study utilising an Escherichia coli secB null 
mutant, have shown that a protein normally associated with SecB, remained unfolded 
and was secreted, albeit with a significantly reduced export efficacy (77). These 
chaperons might therefore have additional roles in protein processing and secretion. 
Mycobacteria lack secB, but are likely to have other cytosolic chaperons to escort 
proteins to SecA.
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Figure 2. The SEC translocase. See text for details.
SecA binds the pre-protein in a clamp-like manner, inserts itself into the SecYEG 
translocon, and the pre-protein subsequently moves through the clamp to enter the 
translocon (78). ATP drives the translocation; it is required for the insertion of SecA 
into the translocon, and the subsequent hydrolysation of ATP causes the dissociation 
of SecA from the pre-protein and a weakening of the binding between SecA-
SecYEG. Sometimes this causes SecA to dissociate completely. However, SecA will 
then once more partially bind to the pre-protein and, upon binding to ATP, cause 
further translocation of the protein (79). This cycle of stepwise translocation 
continues until the process is completed, after which the enzyme SPase cleaves off 
the signal peptide. 
As noted above, the signal peptide might not be required for the localisation to, and 
interaction with, the translocase system. It does, however, appear to have an essential 
role as activator of the translocase. Although the signal peptide of the protein PhoA is 
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not required for association with SecA, Gouridis and colleagues (2009) showed that 
the signal peptide was essential for protein translocation (76). By comparing the 
translocation events of a wild-type protein to the same protein devoid of its signal 
peptide, they showed that this sequence initiated the translocation process by 
lowering the activation energy state of the translocase. It was further responsible for 
the insertion of the N-terminal segment of the protein into the translocase, and for a 
continued association with the translocon throughout the secretion process.
Signal peptides have common features that are similar in prokaryotic and eukaryotic 
cells. Although they vary in length, they typically have a three-domain structure 
where each domain serves a particular purpose. The amino-terminal region, 1-5 
residues long, is positively charged, primarily due to the presence of lysine and/or 
arginine. Site-specific mutagenesis in the signal peptide of maltose-binding protein of 
E. coli has shown that a negatively charged N-terminal leads to a more slowly 
transport of the protein, but the transport is not inhibited per se (80). Other examples 
have shown that exchanging positive residues with neutral residues can completely 
abrogate its ability to be transported (81). The effect of amino acid-substitutions 
presumably depends on the amino acid composition of the rest of the signal peptide, 
which may have overlapping functions. The hydrophobic region that extends from the 
N-terminal to the cleavage site appears to be necessary for translocating the protein 
across the membrane. Enhanced export efficacy can be achieved by making the 
region more hydrophobic or by extending it, while introducing charged residues, or 
shortening the region, can negatively affect protein export (82). Extending this region 
can also compensate for the absence of positively charged amino acids in the N-
terminal, and it has been suggested that both these regions can be involved in 
interaction with SecA (83).
The cleavage site itself seems to adhere quite strictly to amino acid specificity in the 
-3 and -1 position upstream relative to the cleavage site. An alanine in the -1 position 
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Figure 3. Illustration of a signal peptide of the mycobacterial protein MYCP3 (in light green) and 
the cleavage site (marked by red arrowheads).
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appear to be particularly conserved, and only substitutions with Glycine or Serine 
appear to be acceptable (84). Alanine is also predominant in the -3 position, but here 
Serine, Glycine, Valine, Threonine, Leucine, and Isoleucine also seem to be 
permitted. All these amino acids have small neutral side chains, which seems to be an 
important feature for allowing the cleavage site to dock into the catalytic site of the 
SPase. A study revealed that extending the cleavage region with Glutamine up to 9 
amino acids was tolerated for processing of a signal peptide in E. coli (85). Certain 
deviations from a preferred signal peptide structure therefore seem to be acceptable, 
but this is likely dependent on structural properties of the rest of the peptide (86). 
Nevertheless, the AXA-motif is found in the majority of experimentally verified 
signal peptide cleavage sites, suggesting a preference for this sequence for most of 
the proteins that are secreted by the general secretory pathway.
3.2.2 The twin-arginine transporter (Tat) pathway
The Tat secretion system allows translocation of folded proteins across the plasma 
membrane. These proteins carry a signal sequence with a structure similar to the 
sequence used by the general secretory pathway, but it also includes a double arginine 
motif followed by two uncharged residues near the N-terminus (87). In M. 
tuberculosis, the tat genes appear to be essential for growth in culture (88), and 
substrates of the Tat-pathway have also been implicated in interaction with the host 
and bacterial virulence (88,89).
3.2.3 The ESX-1 secretion system
In mycobacteria, a unique secretion system, termed the ESX-1 secretion system, has 
been described. Early secretory antigenic target 6 kDa (ESAT-6) and Culture filtrate 
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protein, 10 kDa (CFP-10) are the two prototypic proteins secreted through this 
system. These proteins are immunodominant antigens of M. tuberculosis, and are 
important for its virulence (90). They are found in the region of difference 1 (RD1), 
the loss of which represented an important attenuation event when the BCG vaccine 
was developed from a pathogenic M. bovis strain. It has been shown that several 
genes in the RD1 locus are required for ESX-1 secretion (91). However, the gene 
locus Rv3616c-Rv3614c, which lies outside the RD1 region, is also involved. 
Rv3616c and Rv3615c are secreted in an ESX-1 dependent manner, and Rv3614c is 
required for secretion of ESAT-6 and CFP-10. Other proteins involved are ATPases 
that provides the energy for translocation, a protease with extracytoplasmic activity, 
and transmembrane proteins whose functions are still not known (91). ESAT-6 and 
CFP-10 form a dimer and are interdependent on each other for stability within the 
mycobacterial cytoplasm. This dimer is escorted to the membrane and delivered in an 
ATPase dependent manner to Rv3870 and Rv3877 that together make up the pore 
spanning the cytosolic membrane (92,93). Interestingly, it is the C-terminal of 
CFP-10 that carries the signal sequence; this 15 amino acid-long peptide is 
unstructured and function as a handle for the protein Rv3871, which target the 
complex for secretion (93).
3.3 Membrane protein integration
Membrane proteins are attached to, or associated with, the membrane of the cell. 
They can be permanently bound to the membrane or temporarily associated with the 
lipid bilayer or with integral membrane proteins. Some proteins are permanently 
associated with the membrane because of their hydrophobic nature, while other 
proteins can exist in more than one state, both water soluble and lipid bilayer-bound. 
The membrane proteins have various functions, including mediating selective 
transport, energy conversion, cell division, extracellular signal sensing, and 
membrane and cell wall biogenesis (reviewed in (94)).
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Many proteins rely on the protein secretion systems for localisation and insertion into 
the membrane, and have intrinsic properties that cause them to be retained in the 
membrane rather than being secreted into the exterior of the cell. This is usually due 
to one or more transmembrane stretches of approximately 20 hydrophobic amino acid 
residues that form an α-helix and are long enough to span the hydrophobic core of the 
lipid bilayer. These transmembrane domains are also passed through SecY during 
translocation, but leave SecYEG laterally into the lipid bilayer. Proteins that are 
inserted into the outer membrane bypass the lateral integration into the plasma 
membrane, and most of them possess an all-β-barrel that crosses the outer membrane 
structure. These proteins require a machinery consisting of the Omp85 outer 
membrane protein and several chaperones for inserting the barrel into the outer 
membrane (94).
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4. Immunology of tuberculosis
This chapter will first outline how the infection is typically established and how it 
develops. It then introduces the components of the immune system, and describe their 
role in combatting the invading tuberculosis pathogen. It will largely be presented as 
the “ideal situation”, where the immune system function adequately to contain the 
infection, and it will not address how the bacterium resists and modulates the immune 
response to its own favour. This will instead be covered in chapter 5.
4.1 The course of infection
Tuberculosis is primarily a disease of the lungs. The infection starts when droplet 
nuclei carrying the bacilli are exhaled by a patient with active disease, and 
subsequently inhaled by another individual, which then becomes infected. The 
droplet is so small that it can remain airborne for several hours. Key factors that 
determine the likelihood of transmission include the number of bacilli expelled into 
the air, the total concentration of organisms in the air in a defined room or area, and 
the duration of exposure to the contaminated air (3). The bacteria reach the bronchi, 
and are phagocytosed by alveolar macrophages, which subsequently invade the 
epithelial layer. The signals secreted by the infected cell attract neutrophils, NK-cells, 
CD4+ T-cells, CD8+ T-cells, which in turn adds to the cytokine- and chemokine 
milieu, recruiting even more cells and model a stable cellular structure at the 
infection site (95). A functional microvascular network develops within this 
granuloma, and an extensive fibrotic capsule forms that eventually separates 
macrophages, granulocytes, foamy macrophages and giant cells, from the 
lymphocytic infiltrate. Eventually the centre becomes necrotic, which in turn leads to 
formation of caseous material as the cells in the granuloma start to die (96). The solid 
caseous material is depleted in oxygen, the pH is low, and it contains enzymes 
released from dead cells. All these factors are hostile to the bacterium, and caseating 
necrosis is linked to a drastic reduction in the number of viable bacilli. In rare 
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instances events occur that lead to softening, or liquefaction, of the caseum, and a 
subsequent destruction of tissue provides direct contact with the bronchi. The 
resulting oxygen rich cavity significantly improves the living conditions for the 
bacilli, and promotes extensive extracellular growth. The establishment of an opening 
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Figure 4. Stages of pathology during tuberculosis infection. See text for details (Russell, 2009)
to the bronchial tree also permits the release of bacteria into the airways (96). The 
ability to contain these organisms is therefore dependent upon a properly structured 
framework within the barriers of the granuloma, and is presumably a prerequisite for 
controlling the disease (97). 
M. tuberculosis is not necessarily confined to the centre of the pulmonary 
granulomas, and can sometimes be found at sites recognised as primary areas for 
lymphocyte proliferation (98). Furthermore, mycobacterial DNA have been detected 
in lung tissue without histological evidence of tuberculous lesions (99), which 
suggests the bacteria can persist outside the cellular infiltrates. Lastly, M. tuberculosis 
can also establish infection in sites outside the lung. This is regarded as a failure by 
the host to retain the bacteria at the primary site of infection. Lymph nodes are the 
most common extra-pulmonary site of infection, but M. tuberculosis can also 
establish infection in the pleural space, genitourinary system, bones and joints, 
central nervous system, abdomen, and the pericardium (100).
4.2 Innate immunity
The innate immunity allows the host to combat pathogens before adaptive immunity 
is activated. The system is often referred to as a non-specific immune system, since it 
recognises conserved structures shared by a whole range of pathogens. The cells of 
the innate immune system can immediately defend against the infection, and 
simultaneously activate the adaptive immune system. 
Alveolar macrophages are likely the first cells to respond to the mycobacterial 
invasion, and are considered to be primary host cells for the intracellular infection. 
The interaction with several types of surface receptors results in phagocytosis of the 
bacterium, and the resulting phagosome matures and fuses with lysosomes to create a 
phagolysosome (101). The lysosome contains hydrolytic enzymes that can efficiently 
degrade microbes, and since these enzymes function optimally at acidic pH, the 
lysosome employs ATP-dependent proton pumps to maintain an acidic milieu at pH 
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4.5-5.0, which in itself is stressful to the pathogen (102). The host cell also starts 
producing reactive nitrogen intermediates (RNIs) and reactive oxygen intermediates 
(ROIs) (103), and at least the latter appears to be essential for control of the bacterial 
infection (104-106). Killing and degradation of the bacilli within the phagolysosome 
is eventually followed by processing and presentation of its peptides on MHC Class 
II molecules on the surface of the host cell. Infected and activated macrophages also 
stimulate immune responses by producing and secreting signal molecules like 
chemokines and inflammatory cytokines. The induction of a strong IL-12 response is 
particularly important, as it stimulates the secretion of INF-γ by several cells of the 
immune system (107,108). If the invasion-event itself does not activate the 
macrophage, this cytokine can stimulate and enhance its killing mechanisms. As they 
become activated, some macrophages become rich in lipid bodies, and are referred to 
as foamy macrophages, while others differentiate into epitheliod cells or merge with 
other macrophages to form multinucleated giant cells (109).
Dendritic cells are also important antigen presenting cells during tuberculosis 
infection, although their functions are more specialised. After ingestion of the 
bacterium, these cells migrate to the draining lymphoid organs where they present the 
mycobacterial antigens to naive T-lymphocytes. This is a key event in the initiation of 
the adaptive immune response (110). Dendritic cells also seem to present antigens to, 
and stimulate, newly arrived lymphocytes in focal lymphocyte-dense infiltrates in 
infected organs (111).
Neutrophils are among the first innate immune cells to migrate to a site of 
inflammation, and influx of these cells are found in acute pulmonary tuberculosis 
(112). They have receptors that can recognise pathogens, and facilitate both 
phagocytosis and stimulate the production of chemokines and inflammatory 
cytokines (113,114). Neutrophils contain high amounts of granules with 
microbiocidal activity, and in response to inflammatory stimulation, they can undergo 
apoptosis and the resulting apoptotic bodies contain a high concentration of these 
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granules. It has been shown that M. tuberculosis-infected macrophages can 
phagocytose these bodies, and thereby increase their own antimicrobial arsenal (115).
Natural killer (NK) cells are large granular lymphocytes that can lyse infected cells 
without prior sensitisation (116). The majority of NK cells have a cytotoxic function, 
and form synapses with infected or abnormal cells, through which they transfer 
cytolytic granules that kill the target cell, including cells infected with M. 
tuberculosis (117). Interestingly, NK cells have also been shown to bind and lyse 
activated regulatory T-cells, whose primary activity is to reduce inflammatory 
responses (118). A small group of NK cells do not lyse cells directly, but instead 
produce INF-γ that adds to the pro-inflammatory environment (119). NK cells can 
also produce IL-22, which promotes phagolysosome fusion within the infected 
macrophages (120). Finally, NK-cells appear to possess antigen capture and 
presentation capabilities, and have therefore been suggested to enhance pro-
inflammatory T-cell responses alongside other antigen presenting cells (121). 
Epithelial cells are non-phagocytic and regarded as fairly resistant to invasion by M. 
tuberculosis, and the bacilli are therefore assumed to cross the epithelium via alveolar 
macrophages and dendritic cells. However, both in vitro culture studies (122-124), 
and observations in human autopsies (99), suggest that these cells can also be invaded 
by mycobacteria. Epithelial cells can respond to cytokine stimulation, and have been 
shown to exhibit antimicrobial activities, including the production of nitric oxide 
(NO) (125) and Lipocalin 2, which seize iron and therefore appear to limit 
mycobacterial growth (126). However, the killing mechanisms exerted by these cells 
is regarded as insufficient for eradicating the bacilli (127). 
4.3 Adaptive immunity
The adaptive immune system comprises cells that are highly specialised against a 
particular pathogen, and it is activated by antigen-presentation and stimulation from 
cells of the innate immune system. The first time a host encounter a new pathogen, 
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specific adaptive immune responses will develop around three to four weeks after 
infection. However, upon re-exposure, cells with antigen-specificities developed 
during the initial exposure, rapidly triggers an efficient response. Adaptive immunity 
is traditionally divided into two branches: cell-mediated immunity and humoral 
immunity, and it is primarily the former that is associated with protection against 
tuberculosis. Humoral immunity is mediated by antibodies, which long have been 
considered by many to be of little help in battling this disease. In cell-mediated 
immunity, the protection is mediated by T-cells that specifically recognise antigens 
presented by antigen presenting cells. They can modulate functions of the innate 
immune system by secretion of signal molecules like cytokines, or they can directly 
kill infected cells. In tuberculosis, the distinction between two T helper cell subsets, 
Th1 and Th2, is believed to be important, and it is Th1 responses that correlates with 
protective immunity (128). This subset consists of CD4+ T-cells that secrete 
proinflammatory cytokines, which enhances the ability of the infected cells to kill the 
intracellular pathogen. Th2-subsets counter-regulates Th1-responses by secretion of 
anti-inflammatory cytokines like IL-4, IL-10 and TGF-β. 
After the bacteria have been phagocytosed by the antigen-presenting cell, they 
primarily reside within vacuoles. The presentation of mycobacterial peptides on 
MHC class II molecules to T helper (Th) cells (CD4+ T-cells), is therefore believed to 
be the most important protective mechanisms against M. tuberculosis (129-132). The 
primary anti-mycobacterial effector function of CD4+ T-cells is the secretion of INF-
γ, which can activate macrophages and enable them to control and eliminate the 
intracellular pathogen, but they also produce other proinflammatory cytokines, 
including IL-2 and TNF-α. TNF-α seems to have at least two roles: it contributes to 
the activation of macrophages (133,134), and it affects immune cell migration and 
localisation within tissues and contributes to the organisation of granulomas. Exactly 
how this cytokine contributes to granuloma formation is not known, but it is known 
to invoke expression of adhesion molecules, along with chemokines and their 
receptors (135,136).
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Proteins present in the cytosol of antigen presenting cells are presented to cytotoxic 
(CD8+) T-cells by MHC class I molecules. Since mycobacteria are primarily thought 
to reside within phagosomes, the role of CD8+ T-cells in tuberculosis infections has 
been thought to be limited. However, mycobacteria have been observed outside the 
phagosome in infected cells (137), and there is evidence of proteins being 
translocated from the mycobacterium-containing phagosome into the host cell 
cytosol(138). CD1 molecules on dendritic cells can also present antigens to CD8+ T-
cells. These molecules are structurally similar to MHC class I, but they have an 
antigen binding groove that is deeper and more hydrophobic, which allows them to 
present both lipids and glycolipids (139). CD8+ T-cells can kill tuberculosis-infected 
cells by secreting perforins and granulysin (140), or by Fas-L-interaction with Fas-
receptors that leads to apoptosis. They also secrete INF-γ during mycobacterial 
infections (141), and this is regarded as a positive contribution of CD8+ T-cells 
towards fighting the infection (142).
Th17 cells distinguish themselves from the Th1 and Th2 subtypes by the secretion of 
IL-17, and are believed to aid in the elimination of pathogens that have resisted the 
efforts of Th1 and Th2 cells. Several cell types express the IL-17-receptor and can 
respond to its stimuli, including dendritic cells, macrophages, lymphocytes, epithelial 
cells, keratinocytes and fibroblasts (143). The responses induced are primarily pro-
inflammatory and lead to accumulation of other cells of the immune system 
(144,145). Th17 cells might also have role in developing long-term protection against 
M. tuberculosis; Th1 memory cells that produce IL-17 appear to respond more 
quickly and populate the lungs faster than Th1 memory cells that do not secrete this 
cytokine (145).
The name of γ/δ T-cells are derived from their unique T-cell receptor composed of a 
gamma and a delta chain, which appear to recognise small phosphorylated molecules 
(146). It is not yet understood how these cells become activated, but they are thought 
to be involved in immune responses during early stages of infection, where they 
facilitate crosstalk between the innate and adaptive immune system (147). During M. 
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tuberculosis-infection, they have been found to produce INF-γ and IL-17 (148,149), 
and to express Fas-FasL and perforin (150). Studies in mice also suggests that γ/δ T-
cells have anti-inflammatory properties, as depletion of these cells or replacing them 
with non-functional cells, was shown to accelerate inflammatory damage during M. 
tuberculosis-infection (151). Lastly, these cells can function as antigen presenting 
cells, and provide sufficient co-stimulatory signals to other cells for induction of 
proliferation and differentiation (152).
Regulatory T-cells are characterised by expression of the transcription factor forkhead 
box p3 (Foxp3), and since many express CD25 on their surface, their phenotype is 
often denominated as CD4+CD25+ cells. Regulatory T-cell expression has been 
associated with bacterial persistence in tuberculosis infection models in mice (153), 
and a rise in cell numbers have been found in human patients with active tuberculosis  
(154,155). Regulatory T-cells produce the anti-inflammatory cytokines TGF-β and 
IL-10, which inhibits the pro-inflammatory activity of all other CD4+ T-cells (156). 
The primary role for regulatory T-cells is probably to limit pathology once a pathogen 
has been eliminated. However, with a persistent organism such as M. tuberculosis, 
these cells might prematurely down-regulate the pro-inflammatory immune response. 
Indeed, increased levels of regulatory T-cells have been found in patients with 
extrapulmonary tuberculosis, which in turn is linked to a failure of the Th1-response 
to kill the bacilli, or at least to limit dissemination (157).
Antibodies have long been thought to offer little protection against tuberculosis. This 
notion is based on the premise that cell-mediated immunity protects against 
intracellular organisms, and B-cells and antibodies protect against extracellular 
infections. Furthermore, early attempts to treat tuberculosis by serum therapy gave 
quite variable results (158). For this reason, the two primary T helper-cell responses, 
Th1 and Th2, have been regarded to be on the opposite ends of the spectrum with 
regard to controlling and eliminating mycobacterial infections. In recent years, the 
rigid distinction between Th1 and Th2 responses have been questioned, and the role 
of B-cells against mycobacterial infections are now considered more favourably. 
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Naive CD4+ T-cells are not committed to a particular cytokine-secretion profile, but 
are influenced by the local environment when exposed to their cognate antigen; if the 
antigen presenting cells secretes IL-12, the T-cells are likely to develop into a Th1 
cell, while IL-4 seems to drive the cell into a Th2 phenotype. Furthermore, both 
nutrients and hormones will influence the outcome of the Th1 and Th2 balance (159). 
The classification is based on the differential set of secreted cytokines, the most 
important being INF-γ secretion by Th1 cells, and IL-4 by Th2 cells. The strict 
division between the two profiles are primarily derived from studies in mice, but in 
humans, the Th1 and Th2 subsets do not adhere so strictly to a certain set of 
cytokines. Furthermore, one subset of activated B cells, the effector (Be) 1 cells, 
secrete INF-γ and IL-12, while the subset Be 2 cells produce IL-4. B-cells also 
produce IL-6, which is an important co-stimulator of T-cells responses, and IL-10, 
which inhibits activation of both macrophages and dendritic cells (160). 
There is also evidence to suggest that antibodies actually do play a role during M. 
tuberculosis-infections. Monoclonal antibodies against arabinomannan on the 
bacterial surface have been shown to prolong survival of M. tuberculosis-infected 
mice (161). Also, passive transfer of monoclonal IgA that targets the major membrane 
protein α-crystallin, have been shown to reduce bacterial load and pathology in mice 
infected with M. tuberculosis, whereas monoclonal antibodies directed against a 
different protein, PstS-1, did not confer protection at all (162,163). The mechanism of 
antibody-protection in tuberculosis is not completely understood. Antibodies can 
presumably bind to the bacilli during brief extracellular exposures, which would 
allow uptake of the pathogen by a wider variety of cells. Furthermore, an Fc-receptor-
mediated endocytosis might lead to more efficient fusion with lysosomes (164). 
Recently, a research group has identified an intracellular IgG-receptor, tripartite 
motif-containing 21 (TRIM21), which binds to the constant region of antibodies 
(165). The intracellular effector mechanism was shown to be protective in cells 
infected with adenovirus, but TRIM21 and similar receptors, as well as their 
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downstream pathways, might also be involved in the protection against a whole range 
of intracellular pathogens, including M. tuberculosis.
4.4 The mouse model for mycobacterial infections
Inbred mice are widely used to study in vivo properties of mycobacteria and host 
immune responses, and since there are extensive similarities between mice and men 
in terms of the basic immune responses, the use of this animal model has provided 
researchers with an invaluable understanding of human tuberculosis. It is frequently 
used to test new vaccine candidates, and to evaluate the effect of newly developed 
drugs. Experiments in mice are relatively inexpensive, and the genetic standardisation 
and minimal variation between animals reduce the number of animals needed in 
experimental groups. 
In both humans and mice, the bacteria primarily target the lungs, and efficient host 
responses rely heavily on the actions of T-cells, INF-γ, and TNF-α (166). 
Furthermore, immune responses can be readily investigated using the vast array of 
reagents that are available against immunological markers in mice. There are also 
some differences that are important to keep in mind. The central necrosis described 
for human granulomas are not typically found in the most commonly used mouse 
strains (167). The organisation of macrophages and lymphocytes is also described to 
be different, as the macrophage- and lymphocyte aggregates found in mice are more 
loosely organised (168). Perhaps as a consequence, there does not appear to be any 
zones of hypoxia in the lungs of these animals during infection, which are 
comparable to the caseous centres in human granulomas (169). However, there are 
genetic differences between mouse strains, just as there are significant differences 
between infected individuals, and certain phenomena can be investigated by selecting 
the appropriate model (170). For example, well-organised granulomas with necrotic 
centres have been described in the lungs of the mouse strain C3HeB/FeJ after 
challenge with M. tuberculosis (171). In conclusion, a complex disease such as 
tuberculosis cannot be fully understood by the use of a single animal model, but it 
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can provide information on key aspects of disease progression and immune 
responses, and by doing so this animal have, and will continue to provide, very 
important pieces of the puzzle.
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5. Mycobacterial modulation of the host response
5.1 First contact and entry
Specific interactions between the mycobacteria and its host start moments after the 
bacilli have gained entry in the lung. Cells of the immune system recognise distinct 
surface features of the bacterium by various classes of phagocytic receptors: Toll-like 
receptors (TLRs), C-lectin type receptors (CLRs), immunoglobulin Fc receptors 
(FcRs) and scavenger receptors (SRs) (101). Some of these receptors will 
immediately prime the immune cells for activation by cytokines, and trigger the 
production of antimicrobial molecules, chemokines, and cytokines. Other receptors 
do not trigger such responses, and may therefore allow a “silent” entry of the 
bacterium into the cell. The outcome of this initial interaction can therefore be 
influenced by the type of receptors expressed by the cells that first encounter the 
bacilli.
The TLRs are perhaps the best described receptors in tuberculosis. TLR-2 recognises 
several mycobacterial proteins and structures, including Hsp65, Hsp70, 19 kDa 
lipoprotein, lipoarabinomannan, and phosphatidylinositol mannoside (PIM) 
(172,173). This interaction has been suggested to induce synthesis of an antimicrobial 
peptide, cathelicidin, which has been shown to be effective against M. tuberculosis 
(174). However, it appears that TLR-2-signalling and responses are dampened when 
the receptor interacts with the secreted mycobacterial protein ESAT-6 (175). 
Furthermore, activation through this receptor can also limit the up-regulation of MHC 
class II by macrophages in response to INF-γ (176). 
Nucleotide-binding oligomerization domain-containing protein 2 (NOD2), which is a 
member of the NOD-like receptor-family, recognises mycolylarabinogalactan, and 
has been reported to be important for cell activation during tuberculosis-infections 
(177). Soluble and membrane-bound CLRs are involved in sensing M. tuberculosis, 
and collectins or integrins that carry the lectin domain, CR3, can facilitate 
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phagocytosis of the bacilli (178). The CLR mannose receptor recognise ManLAM, 
arabinomannan, and mannosylated proteins (179), and has also been shown to be 
important for internalization of bacteria. Both CR3 and mannose receptors are 
associated with a silent entry that does not activate the host cell (180-182). Dectin-1 
is a major beta-glucan receptor that appears to sense heat-stable constituents like 
lipoglycans and α-glucans from the envelope of M. tuberculosis (183). Another CLR, 
Mincle, is a receptor that binds to trehalose 6,6‘dimycolate (TDM), also known as the 
cord factor, which play a role in tissue remodelling and granuloma formation (184). 
TDM is the most abundant lipid to be extracted from virulent M. tuberculosis (185). 
On dendritic cells, DC-SIGN senses ManLAM, arabinomannan, PIM6, α-glucans and 
glycosylated proteins, and it is involved in internalization of M. tuberculosis (186). 
The receptor is also thought to initiate anti-inflammatory responses (187), and it has 
been found to be important in controlling immune responses during acute and chronic 
tuberculosis in mice (188).
From this brief overview, it would appear that interaction with certain receptor types 
favour the initiation of an inflammatory response, while other receptors suppress this 
type of response by allowing the bacilli to enter the cell without activating it. 
However, mycobacteria are likely to interact with several different pattern recognition 
receptors simultaneously as it encounters the immune cells of the host. The initial 
host-pathogen interaction, and the subsequent host response, is therefore multi-
factorial and complex.
5.2 Surviving the phagolysosome
After mycobacteria have entered their host cell by endocytosis, they are immediately 
subjected to host killing mechanisms. Activated macrophages express phagocyte 
NADPH oxidase (NOX2) that generates ROIs (189), and nitric oxide synthase that 
produce RNIs (103). Both ROIs and RNIs can kill the bacteria by interaction with 
molecules like nucleic acids, proteins, lipids and carbohydrates. However, this 
pathogen appears to have different means of resisting this type of stress. It has been 
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suggested that the mycobacterial proteasome can efficiently eliminate or refold 
proteins that have been damaged (190). The bacteria can also prevent damage by 
inhibiting the activities of oxidants. The mycobacterial protein SodA is an iron co-
factored superoxide dismutase that catalyses the dismutation of superoxide into 
oxygen and hydrogen peroxide. This enzyme is secreted through the SecA2 secretion 
channel, and has been found to suppress macrophage activation in vitro and 
inflammatory responses in vivo (191,192). Studies have implicated the activity of 
several other mycobacteria-produced antioxidants in bacterial virulence, including 
catalase-peroxidase, alkylhydroperoxidase C, and Rv3303c (193-195). Expression of 
many antioxidants have been found to be regulated by the sigma factor, SigH, and M. 
tuberculosis mutants that lack this transcription cofactor are highly attenuated in 
mouse models of infection (196,197).
Efficient and complete clearance of the bacteria within the host cell requires fusion of 
the bacteria-containing phagosome with lysosomes containing an arsenal of 
antimicrobial molecules. For this fusion event to occur, the phagosome is required to 
expose several proteins on its surface that will interact with the lysosome. However, 
the bacilli have ways of interfering with the machinery involved in maturation of the 
phagolysosomes. The effect of this can be seen in the atypical retention of the 
GTPase Rab5 to the surface of the phagosome, and a subsequent deficient 
recruitment Rab7 (198). Rab5 is normally found on early, but not late, phagosomes, 
while Rab7 is required for late endosome trafficking. The mycobacterial interference 
therefore seems to take place around the time of Rab5 acquisition. However, one 
experiment showed that even with an abundance of Rab7 on the phagosome surface, 
the phagosome failed to acquire the lysosome-associated membrane glycoprotein 1 
(LAMP1), which is required for phagolysosome fusion (199). This suggests that 
maturation-arrest also can occur after Rab7 has been recruited. Furthermore, 
mycobacterial ManLAM attenuates the activity of the phosphatidylinositol-3(OH) 
(PI(3)P) kinase hVPS34, and by doing so it inhibits recruitment of the early 
endosome autoantigen 1 (EEA1) (200). The latter protein interacts with the soluble 
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N-ethylmaleimide-sensitive factor-attachment protein receptors (SNAREs), which is 
involved in the fusion event. It has also been reported that a SNARE protein called 
cellubrevin exists in an unusual form on mycobacteria-containing endosomes, and a 
structural modification of this protein might be another way to prevent phagosome 
maturation (201). PI(3)P has a role in anchoring many effector proteins on the 
phagosome surface, but by inhibiting recruitment of EEA1 and the lipid kinase 
hVps34, M. tuberculosis prevent PI(3)P from assembling on this surface. The bacteria 
also produce a phosphatase, SapM, that specifically hydrolyses PI(3)P, and the 
combined effect is a near complete depletion of PI(3)P from early phagosomes (202).
Mycobacteria interact with the host tryptophan aspartate containing coat protein 
(TACO) (also called coronin-1), and it has been shown that phagosomes containing 
live, but not dead BCG, co-localize with this protein (203). TACO prevents 
phagolysosome fusion by regulating calcium-dependent signalling processes; a 
sustained calcium influx activate the phosphatase calcineurin, which subsequently 
interferes with the phagolysosome fusion by an unknown mechanism (204). Some 
reports suggests that retention of TACO only occurs in phagosomes where bacterial 
clumping is observed, but the significance of this is not understood (205).
M. tuberculosis possesses 11 proteins of the eukaryotic-like serine/threonine kinase 
family, which is likely to be involved in the modulation of signal transduction 
cascades (206). Most of these enzymes are transmembrane proteins with the active 
domain placed in the bacterial cytosol, which suggests they are involved in regulating 
the bacterial physiology. However, two of the kinases, PknG and PknK, are soluble 
proteins and at least PknG is secreted into the phagosome and eventually reach the 
macrophage cytosol. PknG-deficient bacteria grow well in in vitro-cultures, but in 
macrophages they are attenuated since they cannot prevent lysosomal transfer (207). 
The precise mechanism by which PknG prevents the phagolysosomal fusion is not 
known, but presumably it can phosphorylate one or more host molecules, and thereby 
interfere with signalling pathways that would normally lead to the fusion event. 
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Perhaps one of the most intriguing observations of M. tuberculosis during infection, 
is the ability to escape from the confinement of the phagosome altogether. This has 
been linked to the function of the ESX-secretion machinery, but details of this 
mechanism have yet to be revealed (208).
5.3 Inhibition of signalling pathways
Mitogen-activated protein kinase (MAPK) phosphorylates substrates like 
transcription- and nuclear factors, which in turn lead to production of pro-
inflammatory mediators like TNF-α. Activation of MAPK is caused by signalling 
pathways that involve a cascade of kinases, including p38, extracellular signal-related 
kinases (ERKs) and Jun N-terminal kinases (JNKs). The pathways can be initiated 
upon pathogen entry, and by the influence of cytokines and growth factors. 
Pathogenic mycobacteria, but not non-pathogenic mycobacteria, can inhibit 
activation of p38 and ERK1/2, and by so doing they abrogate the standard pro-
inflammatory host response (209,210). Mycobacteria can also interfere with the 
signalling events that are initiated when INF-γ binds to its receptor on the 
macrophage surface. Under normal circumstances, this receptor will recruit Janus 
kinases (JAKs) that in turn activate the signal transducer and activator of 
transcription (STAT) protein. STAT then translocate to the nucleus where it initiates a 
potent antibacterial response by activating transcription of INF-γ-target genes. While 
M. avium has been found to down-regulate the expression of INF-γ-receptor (211), M. 
tuberculosis has been shown to interfere with the ability of STAT-1 to bind to DNA 
(212). Both actions lead to a reduced transcription of INF-γ-responsive genes.
5.4 Apoptosis
Apoptosis, also called programmed cell death, is a precisely controlled event that is 
either triggered by an extrinsic pathway initiated by the binding of ligands to the so-
called death receptors, or via the intrinsic pathway that involves translocation of 
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cytochrome c from mitochondria to the cytosol. Both pathways activate a cascade 
that leads to degradation of genomic DNA, and eventually fragmentation and 
packaging of cellular contents into vesicles called apoptotic bodies. These vesicles 
are in turn taken up by nearby cells, including macrophages. This is a common and 
efficient response by immune cells for resolving persistent intracellular infections. 
Whether apoptosis is a favourable event for mycobacteria is a matter of debate. 
Apoptosis of the infected cell attracts other immune cells, and the bacteria can spread 
to new potential hosts via the apoptotic bodies. On the other hand, if the infected cell 
fail to undergo apoptosis it might become a safe harbour for the bacteria that can 
replicate unhindered for a prolonged time. Furthermore, it has been shown that small 
apoptotic vesicles derived from infected cells can present mycobacterial antigens to 
T-cells, and thereby stimulate a range of pro-inflammatory responses (213). It has 
been suggested that the bacteria can prevent apoptosis in the early phase of infection, 
which gives them time to adapt and replicate, but that they are unable to prevent this 
form of cell death at later stages. There is little doubt that at least some mycobacterial 
species have the capacity to down-regulate host cell apoptosis, and that this property 
is correlated with increased virulence (214,215). 
Mycobacteria have several mechanisms that can influence host apoptosis. Ca²⁺ can 
facilitate apoptosis by increasing the permeability of mitochondrial membranes, 
enabling the release of cytochrome c (216). M. tuberculosis has been shown to limit 
the Ca²⁺ influx in infected cells by an unknown action of mycobacterial ManLAM 
(217). Bcl-2 is an anti-apoptotic host protein that exert its function by preventing a 
Bax-mediated release of cytochrome c (218). It is inactivated when bound to the pro-
apoptotic protein Bad, however, ManLAM stimulates phosphorylation of Bad, which 
prevents it from binding to Bcl-2 (219). In murine tuberculous granulomas, it has 
been shown that infected macrophages contain increased amount of Bcl-2 and 
reduced amounts of Bax (220). Infection with M. tuberculosis also stimulates the host 
to produce the immunosuppressive IL-10 (221). This interleukin blocks the 
apoptosis-stimulatory abilities of TNF-α by inducing the release of TNF receptor type 
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2 protein. This molecule binds to TNF-α to form an inactive complex, which in turn 
prevents the cytokine from binding to death receptors and stimulate apoptosis. 
Infection with M. tuberculosis also seems to interfere with the expression of 
apoptosis-inducing receptor Fas and its pro-apoptotic ligand FasL. Infected 
macrophages are shown to strongly express FasL, but the expression of Fas appears 
to be down-regulated. Furthermore, up-regulation of FasL expression may induce 
selective immunosuppression by inducing apoptosis of immune cells in the vicinity of 
the infected cell (214,222). Lastly, MPT64 is a mycobacterial protein that is 
implicated in the inhibition of apoptosis, but how it affects the apoptotic pathways are 
not yet understood. Mustafa and co-workers have described how the expression of 
this protein was found to be inversely correlated with apoptosis in infected cells in 
human granulomas (223,224), and this is supported by the recent findings of Kozak et 
al (2011) (225). 
5.5 Metabolic adaptations
Besides inhibiting host killing mechanisms, M. tuberculosis ensures its survival in the 
host by adapting its metabolism to the nutrients that are available at different stages 
of infection. Like other heterotrophs, M. tuberculosis is dependent on at least one 
carbon source for the generation of energy, and for production of proteins, nucleic 
acids and cell envelope components. Specialised uptake systems and pathways are 
involved in the transport and metabolism of available nutrients, and genes involved in 
these pathways are controlled by global and specific transcriptional regulators (226). 
The expression of several genes related to metabolism is upregulated in bacteria 
residing within cells, compared to growth in a standard culture medium, including 
genes characteristic for C2-based metabolism and gluconeogenesis, fad-genes 
encoding enzymes for fatty acid uptake and degradation, and genes for glycerol-3P 
uptake and metabolism. Indeed, fatty acids, and glycerol or glycerol-3P, seem to be 
the favoured source of carbon during intracellular existence.  
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M. tuberculosis has 4 homologous mammalian cell entry (mce) operons that encode 
membrane lipid transporters and enzymes for metabolism and modification of 
imported substrates (227). Deletions mce operons have been shown to attenuate M. 
tuberculosis-virulence in infected mice via the intratracheal route (228), and fatty 
acids have been shown to be required for carbon metabolism in both acute and 
persistent infections in mice (229,230). It is likely that lipids from the host cell are 
essential sources for carbon during infection, although host carbohydrates also appear 
to be used (231). Interestingly, it seems that lipids produced by M. tuberculosis can 
stimulate the host to make nutrients available to the bacteria. Oxygenated forms of 
bacterial mycolic acids induce the formation of foamy macrophages that are rich in 
low-density lipoprotein particles containing cholesterol, triacylglycerides and 
phospholipids. The bacteria can access these lipid droplets, which have been 
suggested to be an important nutrient source for pathogenic mycobacteria in the latent 
stage of infection. In fact, bacteria-containing phagosomes have even been found 
within such lipid bodies (232). Foamy macrophages have also been shown to be 
induced by the cell wall lipid trehalose dimycolate, the cord factor, of M. bovis BCG 
by way of stimulating TLR-2 of the host (233).
5.6 Caseation, liquefaction and spread
The accumulation of caseum in the granuloma appears to be linked to the formation 
of foamy macrophages, since the lipids of the caseum are the same as those involved 
in foam-cell formation (234). As mentioned previously, the caseum forms after the 
immune cells have been organised into the granuloma structure, and its primary 
purpose is to form a physical barrier from which the bacteria cannot immediately 
escape. In some cases, however, a build-up of tuberculin-like products seems to cause 
a response that eventually result in a liquefaction of the solid caseum (235). The 
liquefaction is probably driven by hydrolytic enzymes that are either produced by the 
surrounding host cells, or by enzymes that are already present within the caseum. 
Mycobacteria have been suggested to produce inhibitors of these enzymes to delay an 
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early destruction of the tissue it has invaded. This would explain why the tuberculous 
lung under normal circumstances do not liquefy for several weeks, if at all (236).
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6. The substrains of BCG
After Albert Calmette and Camille Guérin had attenuated a pathogenic strain to 
develop the vaccine M. bovis Bacille Calmette-Guérin (BCG), and it had been proven 
to be both protective and safe, large-scale vaccination programs were initiated. Many 
countries received their own batch of the BCG Pasteur strain culture for local 
maintenance and distribution. However, variable sub-culturing practices at these 
facilities eventually lead to the rise of substrains with divergent genetic content and 
alterations in the regulation of gene expression. Proteomic studies and genotyping in 
later years have shed some more light on the evolution of these substrains, and based 
on this work they have been divided into 4 groups based on similarities and 
divergence from the originating M. bovis strain. This division is illustrated in Figure 
5. 
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Figure 5. The division of BCG into early and late strains (Adapted from Brosch, 2007) 
One of the major differences between these groups is the loss of region-of-difference 
2 (RD2) from the BCG strains that often are referred to as late strains (Group III and 
IV in Figure 5) (237,238). Recently, the RD2 region was shown to contribute to the 
virulence of a wild type M. tuberculosis H37Rv strain, when compared to a 
H37Rv:ΔRD2 in both an in vitro and murine model (225). The authors described 
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reduced bacterial burden and lung pathology at early time-points for the gene knock-
out-strain. The late BCG strains also lack the gene mma3, which is involved in 
synthesising methoxymycolic acids (239), and a missense mutation in the start codon 
of sigK leads to a greatly reduced expression of MPB70 and MPB83 (240-242). Gene 
deletions and missense mutations are not the only modifications that differentiate the 
BCG substrains. The alterations through cultivation have also led to duplication of 
genes (37,243). Two duplication units have been described, DU1 and DU2; the 
former appear to be unique to the substrain BCG Pasteur, while the latter is more 
widely distributed. Within the DU2 unit lies the gene encoding the sigma factor SigH, 
which has been found to increase expression of multiple antioxidants during 
oxidative stress (244). This region also harbours whiB1 and whiB3 that belongs to the 
WhiB family of transcription factors, which have been found to regulate virulence, 
cell division and stress responses. WhiB1 have been found to be duplicated in all 
BCG strains, while the expression of WhiB3 is increased 9-fold in BCG Pasteur 
compared to BCG Japan and M. bovis (245). Also, expression of the oxidoreductase 
Rv1774 has been described to be up-regulated in BCG Pasteur when compared to 
BCG Russia, which is linked to the loss of a repressor that lies within RD14. BCG 
Pasteur is the only BCG strain that lacks this region (246). To complicate the picture 
further, Chen and colleagues (2007) found that BCG Japan (group I), BCG Moreau 
(group I), and BCG Glaxo (group III) do not produce two cell wall lipids that have 
been associated with virulence in M. tuberculosis and M. bovis (247,248). The lipids 
were found to be expressed in other BCG strains representing all the four groups. The 
phylogenetic distance from the original M. bovis strain does therefore not necessarily 
represent a gradual increase in attenuation and decrease in vaccine efficacy; the BCG 
substrains appear to differ in their properties in a less predictable manner. In fact, the 
efficacy of the BCG vaccine has long been a matter of controversy. After it was 
determined to be both safe and protective, a close look into the vaccination programs 
showed inconsistencies in the reported results, and a meta-review published in 1994 
describe reports of BCG efficacy ranging from 0% to 80% (249). It has been 
speculated that an ‘over’-attenuation of certain BCG substrains might be the cause for 
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these highly variable results (250). However, other meta-reviews that have evaluated 
vaccine programs in humans and animal trials, conclude that the administered BCG 
vaccine strain could not be used as a determinant of overall efficacy (251,252). 
Another suggested factor is variable handling of the vaccine leading to differential 
numbers of viable bacilli per vaccine dose. Situations where these differences might 
come into play include vaccine production (both cultivation and the process of freeze 
drying), storage, reconstitution and preparation. In 1948, Heimbeck showed that live 
but not dead BCG bacilli protected vaccinated nurses against tuberculosis (253), 
indicating that the metabolic activity, and secretion of proteins, is important for 
inducing a protective immune response. It has also been suggested that differences 
between the vaccinated individuals, like the presence or absence of resistance and 
susceptibility genes, and nutritional status, have influenced the outcome of these 
trials. Another confounding factor is possibly the exposure and interference of non-
pathogenic environmental mycobacteria like M. avium (254,255). However, while 
dead environmental bacteria might theoretically interfere with the efficacy of BCG 
vaccination, live environmental bacteria actually seem to offer some protection by 
secreting antigens that are cross-reactive. Non-pathogenic mycobacteria may also 
influence results of the BCG trials in less obvious ways. The negative control group, 
consisting of non-vaccinated individuals, will be exposed to environmental 
mycobacteria to the same extent as the BCG vaccinated group during the trial, and 
the efficacy of the BCG vaccine might be occluded by any protection that these 
species might offer. This could explain the poor results noted for some of these trials. 
Today, the BCG vaccine is generally viewed as insufficient for protecting adults from 
pulmonary tuberculosis. However, it is still regarded to be efficient against 
tuberculous meningitis and miliary disease in children, and is therefore still 
recommended in countries with high prevalence of tuberculosis.
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7. Aims of the study
7.1 Overall aim
The overall aim of the current thesis was to increase the understanding of bacterial 
factors for mycobacterial pathogenicity with a particular focus on secreted proteins.
7.2 Specific aims
• To determine the best signal peptide prediction algorithm for mycobacterial 
proteins, using data sets verified by proteomic methods.
• To evaluate that nature of proteins with a predicted signal peptide, but that 
remain uncleaved and enriched in the membrane fraction.
• To investigate the pathology in mice infected with either of two BCG strains, 
BCG Russia and BCG Pasteur, that differ in their genetic content due to 
alterations arisen during in vitro culturing.
• To study the in vivo pattern of expression of mycobacterial proteins within 
murine lungs by using immunohistochemistry.
• To study the in vivo pattern of expression of mycobacterial proteins within 
human tuberculous lesions obtained from lungs and lymph node biopsies.
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8. Materials and methods
8.1 Ethical considerations
The animal experiments in paper III were performed according to protocols approved 
by the Norwegian Animal Research Authority. Ethical clearance for the use of human 
biopsies was obtained from the regional ethical committee in Norway.
8.2 Paper I
Construction of validation sets 
To test the signal peptide prediction algorithms we created two validation sets: a 
positive validation set that contained proteins known to be cleaved by signal 
peptidase and where the exact cleavage site was known, and a negative validation set 
consisting of proteins that we knew were not cleaved. We included only proteins 
where the mature sequence had been verified experimentally. Some were found in 
previously published literature, but we also used novel data generated by our group. 
In total, we included 57 proteins in the positive validation set, and 61 proteins in the 
negative set.
Prediction algorithms 
We tested the performance of 9 different signal peptide prediction algorithms: 
SIGCLEAVE, PrediSi, SPEPLip, Signal-CF, Signal-3L, and the hidden Markov 
model and neural network method from versions 2 and 3 of SignalP. The selected 
algorithms were free of charge and publicly accessible from their respective web 
interface. Since these programs have been developed to separately analyse 
eukaryotes, Gram-negative bacteria and Gram-positive bacteria, we chose the Gram-
positive option since mycobacteria are regarded to belong to this group. The 
exception was SIGCLEAVE, which only had options for eukaryotes and prokaryotes.
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Protein sequence data 
The prediction algorithm that performed best on our positive and negative validation 
sets was used to analyse proteins from all mycobacterial proteome annotations that 
were available at the time we conducted our study. These included two separate 
annotations of M. tuberculosis isolate H37Rv, M. tuberculosis isolate CDC1551, M. 
tuberculosis isolate H37Ra, M. bovis, M. bovis BCG Pasteur, M. leprae, M. avium, M. 
avium subsp. paratuberculosis, and M. smegmatis.
8.3 Paper II
Preparation of mycobacterial proteins for proteomic analyses
We harvested colonies of M. tuberculosis H37Rv grown on agar plates for around 4 
weeks. The colonies were mixed with an extraction buffer that contained protease 
inhibitors, and transferred to tubes with glass beads. The bacilli were subsequently 
lysed by bead beating. For preparation of whole cell lysate, the solution was 
centrifuged and the supernatant containing the proteins was collected. To isolate 
membrane proteins, the supernatant was treated with the detergent Triton X-114 to 
obtain lipophilic proteins from the lipid phase.
Proteins from each preparation were further separated by size using an SDS-PAGE 
gel electrophoresis system, and each lane was divided into smaller segments for 
digestion with trypsin. The enzyme trypsin cleaves peptide chains at the carboxyl side 
of lysine and arginine, except when these amino acids are followed by a proline. The 
mass spectrometry technique requires the proteins to be broken down into smaller 
fragments for analysis. By using trypsin digestion, the proteins are broken into 
smaller peptides with a mass that can be matched to theoretical peptides acquired by 
in silico trypsin cleavage of annotated protein sequences. The mass of a peptide, and 
the masses of its fragments following fragmentation, gives the peptide a unique 
peptide sequence tag that is used to identify the peptide in a protein database.
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Identification of proteins by mass spectrometry
Peptides were detected using an Orbitrap mass spectrometer, which generated a list of 
peptide sequence tags representing the most abundant peptides in our samples. These 
were identified by searching through databases of theoretical peptides generated from 
the Tuberculist database made available by the Pasteur Institute, and the CMR-TIGR 
database. Proteins were validated statistically based on the score of the identified 
sequence tags. If a particular protein was represented by only a single peptide, this 
peptide was required to have a higher score to be accepted as a positive identification, 
than if a protein was identified by two or more peptides.
Label free quantification of proteins based on MS data is a relatively new 
development. We calculated the abundance of all identified proteins by calculating an 
emPAI value for each protein, and by further dividing this value by the sum of the 
emPAI values for all identified proteins in the sample. The emPAI value of a protein 
is calculated by dividing the parent ions of observed peptides by the number 
theoretically observable peptides for a particular protein.
8.4 Paper III
Infection of mice
We grew two BCG strains, BCG Russia and BCG Pasteur, in parallel in 7H9 culture 
medium. When the bacilli had reached mid-log phase, we broke up any large bacterial 
aggregates that might be present in the medium, and froze the suspension at -80°C. 
Female mice of the C57BL/6 strain were infected intranasally with either of the two 
BCG strains. The infection inoculates were verified to contain the same number of 
CFU, and to be similar with regard to clumping. After infection, we sacrificed groups 
of mice at various intervals for 17 months. The right lung was removed and 
homogenised for enumerating bacterial colony forming units (CFU), and the left lung 
was perfused with formalin and later embedded in paraffin for histological 
examination. 
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Histology and immunohistochemistry
The paraffin embedded lungs were cut in serial sections, and one section from each 
lung was stained with hematoxylin and eosin to investigate lung pathology. We 
defined 4 types of regions that were measured separately: macrophage-dominant 
areas, lymphocyte-dominant areas, bronchus-associated lymphoid tissue (BALT), and 
areas with no observable pathology. We then measured the total size of each of these 
areas, which was compared to the total size of the lung section. The remaining 
paraffin sections were used for immunohistochemistry. These were stained using a set 
of rabbit polyclonal antibodies that were specific to somatic (cytoplasmic and 
membrane) and secreted mycobacterial proteins, and we also used antibodies 
developed against a BCG whole cell lysate (see Table 1). Visualisation of staining 
was achieved with biotinylated secondary goat anti-rabbit antibodies, streptavidin-
coupled horseradish peroxidase, and finally a 3-amino-9-ethylcarbazole (AEC) 
substrate chromagen. We determined the ratio of stained cells versus unstained cells 
in the 4 types of regions outlined above, and we made a semi-quantitative 
measurement of the staining intensity. 
Statistical analyses
All statistical analyses were performed using the SPSS Statistics software. Values 
were expressed as the median. A two-tailed non-parametric Mann-Whitney U-test 
was used to compare data from the two BCG strains, and for correlation between 
parameters we used Spearman’s rank correlation for non-parametric data.
8.5 Paper IV
Collection of samples
We obtained biopsies from patients with pathologic findings confirmed to be caused 
by M. tuberculosis complex organisms. In total we studied 17 cases of tuberculous 
lymphadenitis and 4 cases of pulmonary tuberculosis. Twelve cases of non-
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tuberculous inflammation were used as controls. In addition, lung tissues from 11 
mice infected with M. tuberculosis, and 4 uninfected control mice were included.
Histology and immunohistochemistry
Staining with hematoxylin and eosin, as well as immunohistochemistry, were 
performed as described for paper III.
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9. Summery of results
9.1 Paper I
In paper I, we investigated the accuracy of 9 prediction algorithms for predicting the 
presence of a signal peptide, and the respective signal peptide cleavage site, in 
mycobacterial proteins. They were tested on two validation sets; a positive set where 
all the proteins had been experimentally confirmed to harbour a signal peptide, and a 
negative set that contained proteins without an N-terminal signal peptide.
• The hidden Markov model of SignalP v 3.0 was the best performing algorithm. 
It correctly detected the presence of a signal peptide in all proteins in the 
positive set, and it did not produce any false positive results in the negative 
data set. This algorithm also was the best performer for detecting the correct 
cleavage site; 45 of the 57 cleavage sites were correctly predicted.
• Using the hidden Markov model of SignalP v 3.0, we predicted secreted 
proteins from several mycobacterial proteomes. From the list, we excluded 
proteins predicted to have transmembrane helices in the mature protein 
sequence, with the presumption that these are membrane proteins. The ratio of 
secreted proteins ranged from 7.8% in M. smegmatis, to 10.5% in M. leprae.
• Signal peptide prediction of two different protein annotations of the M. 
tuberculosis H37Rv genome gave variable results; in one annotation, 13% of 
the proteins were predicted to have a signal peptide, but only 11% in the 
second annotation.
9.2 Paper II
In paper II, we investigated the nature of membrane proteins with a predicted signal 
peptide.
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• We identified 30 proteins enriched in the membrane fraction, with positive 
identification of peptides that either completely or partially overlapped with 
the predicted signal peptide sequence.
• Structurally, these proteins were similar to proteins known to be cleaved by 
signal peptidase, but we found more variation in the -3 position relative to the 
cleavage site.
• Some of the proteins had a transmembrane domain that spanned the predicted 
cleavage site, which might make it unavailable to cleavage by signal 
peptidase. However, this does not explain the lack of processing for the 
majority of these proteins.
9.3 Paper III
In paper III, we studied the course of infection with two BCG strains in mice, and 
investigated the in vivo expression of secreted and somatic mycobacterial proteins.
• BCG Pasteur was more persistent than BCG Russia in our mouse model; while 
BCG Russia was cleared from the lungs after 4 months of infection, BCG 
Pasteur persisted until the experiment ended 17 months after infection.
• There was greater pathology in lungs of mice infected with BCG Pasteur, 
consistent with the higher bacterial load.
• Immunohistochemistry revealed the in vivo protein expression to be similar 
between the two BCG strains.
• For both BCG strains, immunohistological staining revealed host cells located 
in the normal lung parenchyma with a high load of bacterial antigens.
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9.4 Paper IV
In paper IV, we investigated the staining patterns of polyclonal antibodies specific for 
secreted and somatic M. tuberculosis proteins within human lungs and lymph node 
tissues.
• Secreted proteins were detected more frequently in pulmonary granulomas, 
than in lymph node granulomas.
• In certain cases, major secreted proteins were only detected in necrotic centres, 
and not in the cells of the granuloma.
• The staining pattern varied between the secreted proteins. Only MPT64 was 
expressed in all granulomas in both lung and lymph node lesion.
• Staining of Mce1A was detected more frequently in organised granulomas, 
compared to the regions without proper granuloma formation.
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10. Discussion
From the moment M. tuberculosis enters its host, there is a two-way interaction 
between the two organisms. The host recognises structural features of the bacilli, and 
mounts responses to contain and kill it. The bacterium, on the other hand, does 
whatever it can to resist and interfere with the killing mechanisms of the host, 
something it can do successfully for many years. It manages this by way of secreted-
and membrane molecules that specifically interact with host proteins and disrupts and 
modulates host responses. However, the exposure of such molecules also generates 
specific immune responses by the adaptive immune system, and might become 
important immunogens during the course of infection. A full comprehension of the 
identity, location and expression pattern of such proteins is therefore crucial to 
understand the biology of this pathogen, and it paves the way for making enlightened 
decision when developing new vaccines, diagnostic tools, and drugs.
We sought to tackle different aspects of research into this field. 
10.1 Prediction of signal peptides
The use of prediction algorithms in molecular biology research has greatly pushed the 
biology field forward. It has made it possible to screen and interpret large amounts of 
data, and it can provide information about properties of proteins based solely on the 
gene sequence information. However, their inherent nature is to extrapolate the 
information from a limited set of experimentally acquired data to new sequences, 
which in many cases encode proteins with unknown properties and destinies. The 
quality of these prediction programs is therefore not only determined by the 
architecture of the algorithm, but also the data sets that are used to train them. 
The prediction of N-terminal signal peptides from proteins that are processed through 
the general secretory pathway seems to be one of the success stories in the field of 
prediction algorithms. Several algorithms have been developed for this type of 
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prediction, and they vary both in design, and the size and quality of the training sets. 
Perhaps signal peptides lend themselves particularly well for this type of prediction. 
They contain three distinct domains, from the positively charged N-terminal, via the 
hydrophobic region, to the C-terminal part that contains two quite conserved amino 
acids in the -3 and -1 position relative to the cleavage site. Some variations can been 
found between the domains of life, and the existing prediction programs have 
therefore created separate algorithms for eukaryotes and prokaryotes, and many also 
differentiate between Gram-negative and Gram-positive bacteria. The prediction 
algorithms are trained on protein sequences from a large number of species within 
these groups.
Because of their unique cell wall, mycobacteria do not comfortably fall into either of 
the Gram stain-based categories. They have traditionally been grouped together with 
Gram-positive bacteria, and mycobacterial proteins have been part of the training sets 
of prediction algorithms created for this group. Over the last 20-30 years, 
experimental work by several laboratories has established the mature sequence of 
several secreted and somatic proteins in a variety of mycobacterial strains. Many of 
these were found to be cleaved at the N-terminal, and were therefore truncated 
compared to the annotated protein sequence. These findings provided us with an 
excellent opportunity to create validation sets to test the performance of available 
signal peptide algorithms on mycobacterial proteins. In total, we found 57 proteins 
with the experimentally verified signal peptides and cleavage sites, and we also 
created a set of 61 proteins that we knew were not cleaved. The amino acid sequences  
from these proteins were submitted to 9 different signal peptide prediction 
algorithms, which were subsequently ranked according to performance on the 
positive and negative set. 
The best performer was SignalP v3.0 hidden Markov model. This algorithm correctly 
identified the proteins that harbour a signal peptide, and the proteins that do not, and 
it also correctly predicted the cleavage site for 45 of the 57 secreted proteins. In fact, 
the second best performing algorithm was the previous version, v2.0, of the same 
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algorithm. This version also correctly predicted the presence or absence of signal 
peptides, but it only found the correct site of cleavage for 39 of the proteins. As 
already stated, an essential part of creating well performing prediction algorithms is 
to train them on a carefully chosen training set. The evolvement of the SignalP hidden 
Markov model from version 2.0 to 3.0 is a good example of this. The only 
improvement made between the two versions was to remove dubious sequences from 
the original training set to create a more solid set with verified sequences and 
cleavage sites. The result, as measured using our validation sets, was an improvement 
in cleavage site prediction from 68.4% to 78.9%. The training set of this algorithm is 
made up of protein sequences from a broad range of Gram-positive organisms, where 
each species is represented by only a handful of protein sequences. As mentioned 
above, we were uncertain if it was correct to group mycobacteria alongside Gram-
positive organisms due to their unique cell wall, and if the signal peptide prediction 
consequently would suffer due to differences in signal peptide structures. As it turns 
out, the detection of signal peptides in our validation set was faultless, but with an 
accuracy of 78.9%, there seems to be room for improvement for the cleavage site 
prediction. However, this inaccuracy does not appear to be unique to mycobacterial 
protein sequences. When the developers of the SignalP v3.0 hidden Markov model 
cross validated their algorithm using sequences from Gram-positive bacteria in their 
training set, they found the cleavage site prediction accuracy to be 81.6%, which is 
quite close to our result. This cross validation also revealed that the Neural network 
algorithm actually performed better than the hidden Markov model, as this predicted 
85% of the cleavage sites correctly. In comparison, the prediction accuracy of this 
algorithm was only 50.9% in our validation set. In conclusion, both the algorithm 
architecture and the choice of sequences used to train it, is important for the 
performance on protein sequences from a given organism. By using validation sets 
consisting of mycobacterial protein sequences, we identified the best available 
algorithm for finding signal peptides and their cleavage sites in this organism. 
However, for other species, a different algorithm might perform better, and it is only 
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through work such as ours the optimal algorithm can be found for any given 
organism.
We decided to use SignalP v3.0 hidden Markov model to analyse all the available 
protein annotations from different mycobacterial species that were available at the 
time, including two annotations of the same M. tuberculosis H37Rv strain. Between 
10.8% and 13.3% of the proteins were predicted to harbour a signal peptide. 
Interestingly, the number of predicted signal peptides were higher in one of the M. 
tuberculosis H37Rv proteome annotations, at 13% in the Sanger annotation, 
compared to the TIGR annotation where 11% of proteins were found to have a signal 
peptide. Finding more of these conserved features, which the N-terminal signal 
peptide represents, suggests the Sanger annotation have performed better with regard 
to correctly predicting the N-terminal starting point of proteins. Indeed, a study by de 
Souza et al (2008) have confirmed that the Sanger annotation is the better annotation 
of the two (52). 
As mentioned in chapter 3.2.1, the general secretory pathway is also used to integrate 
proteins with signal peptide into the membrane. Characteristic features of most 
membrane proteins are hydrophobic regions that can span the cell membrane, often 
referred to as transmembrane regions. To make an estimate of the number of proteins 
that were secreted rather than integrated in the membrane, we used a second 
algorithm for predicting transmembrane regions downstream of the signal peptide 
cleavage site. As a consequence, between 25% and 30% of proteins with a predicted 
signal peptide were removed from the list of potentially secreted proteins.
To conclude, we showed there was quite a variation in the performance between 
programs for identifying protein processed through the general secretory pathway and 
their respective cleavage sites. Our results showed that the SignalP v3.0 hidden 
Markov model scored top marks for predicting the presence or absence of signal 
peptides in our positive and negative data sets, and it was the best algorithm for 
predicting the exact peptide cleavage site. 
75
10.2 Proteins with predicted signal peptides enriched in the 
membrane fraction
In paper I, we predicted the number of secreted proteins from several mycobacterial 
proteomes based on the following assumption: Proteins with signal peptides that did 
not contain a transmembrane region in the mature amino acid sequence were 
regarded as secreted. The premise was thus: all proteins that meet these criteria are 
processed through the general secretory pathway, the signal peptide is cleaved off and 
removed from the mature protein, and that the protein is subsequently released to the 
exterior of the cell. This was a deliberate simplification; we knew that the prediction 
for some of these proteins might be incorrect, but furthermore, we were aware of two 
studies that had characterised the membrane fraction of Bacillus subtilis and found 
that it contained 31 proteins with a characteristic N-terminal signal peptide sequence 
(266,267). Unfortunately, the authors of these articles had not convincingly shown 
that these proteins were not contaminants from the cytoplasm, neither did they 
determine if the predicted signal peptides had been removed. In our group, we had 
previously characterised proteins in the membrane fraction of M. tuberculosis H37Rv, 
where we found 37 proteins with predicted signal peptides that had not been removed 
(54). We now wanted to further characterise these proteins to identify any 
characteristic features that might explain why these proteins are enriched in the 
membrane rather than secreted.
To address the issue of possible contamination from cytosolic proteins, we also did a 
proteomic analysis of a whole cell lysate of M. tuberculosis H37Rv and determined 
the relative concentration of these proteins in the respective samples. This way, a 
protein identified in the membrane fraction, but with a higher relative concentration 
in the whole cell lysate, would be regarded as a soluble protein and a contaminant of 
the membrane sample. This turned out to be the case for 7 of the 37 proteins. The 
other 30 proteins, however, were found to be truly enriched in the membrane fraction. 
For proteins such as these, the hydrophobic property of the signal peptide itself might 
be required for retention in the membrane, in which case the inability of the signal 
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peptidase to access and process the cleavage site is important for the correct 
localisation. The question is why these cleavage sites are not processed by the 
peptidase. Structurally, they are similar to signal peptides in proteins that are known 
to be cleaved, but we did notice that an alanine in the -3 position relative to the 
predicted cleavage site was less conserved for the uncleaved proteins, where more 
variation was observed. We also noticed that some of these proteins had a predicted 
transmembrane region that encompassed the cleavage site, which might therefore 
become unavailable to the signal peptidase located on the cytosolic side of the 
membrane. However, neither of these factors explains why all 30 proteins were 
retained in this fraction.
10.3 BCG strain variation and its influence on the course of 
infection in mice
Bioinformatic tools and proteomic analysis of in vitro cultures will by themselves tell 
us little about the in vivo expression of proteins, and how their expression might 
contribute to virulence throughout infection. Experimental infection in mice is a well-
established tool to investigate in vivo behaviour of mycobacteria and host responses. 
As mentioned in chapter 6, BCG strains have been divided in groups based on their 
phylogenetic distance to the originating BCG strain that were created at the Pasteur 
Institute by Calmette and Guerin in 1921. It has been argued that strains 
phylogenetically closer to the original BCG strain are more virulent and therefore 
also more potent as vaccines, compared to the strains that have diverged more. 
However, studies comparing vaccine efficacy of different strains have not been 
conclusive with regard to this aspect. We therefore decided to infect mice with BCG 
strains at either end of this spectrum, the “early” strain, BCG Russia, and the “late” 
strain, BCG Pasteur, to describe if the relatively minor differences in genetic make-up 
would influence the course of infection in mice. 
We selected a commonly used mouse strain as our animal model of choice. The 
C57BL/6 strain is considered relatively resistant to mycobacterial infections. This is 
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at least partially attributed to the gene called natural resistance-associated 
macrophage protein 1 (nramp1), which appears to be absent from highly susceptible 
murine strains (268,269). The C57BL/6 strain is also considered to initiate pro-
inflammatory Th1-type of responses following mycobacterial infections. The mice 
were infected intranasally to deliver the bacteria directly to the lungs, and we 
followed the course of infection for almost one and a half year. Compared to the dose 
of infection, the number of bacilli dropped during the first months of infection for 
both strains. This was expected, as the fall in bacillary load has been described 
previously for BCG strains (270,271). However, while the number of BCG Pasteur 
stabilised at a low number, BCG Russia got cleared from the lungs by 7 months 
infection. Furthermore, we found more macrophage- and lymphocyte infiltrates in the 
lungs of mice infected with BCG Pasteur, compared to mice infected with BCG 
Russia. Since BCG Pasteur was more persistent and induced more pathology in mice 
than BCG Russia, it can be considered as the more virulent strain of the two in our 
infection model. There is no doubt that BCG Pasteur has undergone more genetic 
changes than BCG Russia, compared to the original BCG strain. Since these changes 
have arisen through cultivation in artificial growth medium, it would be a reasonable 
assertion that BCG Pasteur has become more attenuated than BCG Russia. Analyses 
of genomes from several BCG strains have indeed revealed the loss of gene regions 
that are associated with virulence in mycobacterial species (37). However, other 
alterations have lead to duplication of genes, and at least in one case, the loss of a 
gene repressor caused increased expression of the affected proteins (37,272). Among 
the proteins found to be up-regulated in late strains are antioxidants, possibly to 
detoxify by-products of aerobic metabolism during in vitro-cultivation (273). 
However, increased expression of antioxidants also improves bacterial survival inside 
host cells by suppressing oxidant-dependent immune responses. In line with this, Jain 
and colleagues found that a recombinant BCG Denmark overexpressing iron-
cofactored superoxide dismutase resulted in reduction of apoptosis and microbiocidal 
potential of macrophages, and reduced production of IL-10 and INF-γ, compared to 
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the wild type strain. Furthermore, the recombinant BCG strain conferred less 
protection against M. tuberculosis in guinea pigs and mice (274).
As BCG Russia disappeared from the mouse lungs, so did the macrophage- and 
lymphocytes aggregates. However, the bronchus-associated lymphoid tissue that was 
formed following the initial infection persisted until the end of the experiment for 
both BCG Russia and BCG Pasteur. These lymphoid follicles are believed to be 
important for T-cell priming and B-cell education in the host defence against 
respiratory pathogens. However, the cytokine environment in this tissue is thought to 
shape immune responses that limit immunopathology, perhaps to stimulate prolonged 
and persistent priming of lymphocytes, rather than pro-inflammatory responses that 
can stimulate bactericidal activities of lymphocytes and antigen presenting cells. This 
might be why this tissue has been found to be a reservoir of latent infection with 
latent herpes virus MHV-68 (275). Regulatory T-cells is a lymphocyte population 
with immunosuppressive properties, and might contribute to the anti-inflammatory 
BALT environment. Following infections with M. tuberculosis in mice, these cells 
have been found in all lymphocyte aggregates, including BALT (153). By staining 
regulatory T-cells using antibodies against the transcription factor FoxP3, we found 
that this was also the case for mice infected with BCG strains. A persistent BALT that 
continuously prime lymphocytes with antigens from pathogens it has been exposed 
to, might facilitate a rapid and protective response upon re-infection. This can be 
particularly advantageous in epidemic situations where the risk of re-exposure is 
high. On the other hand, suppression of immunopathological responses are 
considered harmful for many infectious diseases, including tuberculosis, and mice 
that are depleted of regulatory T cells have been shown to better control M. 
tuberculosis-infection than their wild type counterparts (153). We found no evidence 
for prolonged and persistent presence of bacilli in BALT in our mice, and BALT was 
present in all mice even if no bacilli could be cultivated from their lungs. However, 
after 3 months of infection, there was a significant correlation between the percentage 
of BALT and detectable CFU from lungs of mice infected with BCG Russia. The 
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situation was different from mice infected with BCG Pasteur, where the CFU 
correlated with both macrophage- and lymphocyte dominant areas. Perhaps this 
indicates that the bronchi-associated lymphoid tissue might be a last refuge for the 
bacteria before they are completely cleared from the lungs. 
10.4 In vivo mycobacterial protein expression in BCG-
infected mice
Despite a significant difference in the ability to persist in the mouse lungs, there was 
a high degree of similarity between the two BCG strains with regard to staining 
patterns of polyclonal antibodies specific to selected mycobacterial proteins. For both 
strains, the ratio of stained cells was as expected much higher in macrophage-
dominant lesions than the other areas investigated. Even if the infiltrates induced by 
mycobacterial infections in mice are less structurally defined than those found in 
humans, the aggregation of macrophages represents the primary site for bacillary 
presence during infection. In conclusion, we were able to show that the bacilli 
produced both somatic and secreted proteins during in vivo infection, and that the 
level of expression was similar between the two strains. Proteins expressed by a 
metabolically active BCG after vaccination, and during its relatively short-lived 
intradermal infection, represent the primary source of immunogens that will provide 
protection against subsequent exposure to a pathogenic mycobacterium (253). 
We made an unexpected and interesting observation in the normal lung parenchyma. 
Immunohistochemistry revealed cells that carried a heavy bacterial antigenic burden. 
This not only suggest an inability of the host cells to eliminate the infection, but also 
that they seem incapable of alerting other immune cells of the on-going infection. 
These observations illustrate the ability of mycobacteria to survive the hostile 
environment of the cell, and to turn off, or not trigger, signalling from the infected 
cell to its surroundings. There are many who argue that M. tuberculosis can enter a 
dormant state during infection, a feature that has been linked to the establishment and 
maintenance of latent tuberculosis. In this scenario, the bacilli are thought to almost 
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cease all metabolic activity, and it has also been suggested they take on a form where 
they are devoid of many of its antigens, and thus become almost invisible to the host. 
Our observations are different. The bacteria in these particular cells seemed to both 
replicate and to be metabolically active as evidenced by strong staining of both 
somatic and secreted proteins. Without the aid of other immune cells, the infected 
cells are deprived of the stimuli they require to fight the bacteria, which in turn might 
provide the bacilli a safe harbour where they can replicate and persist for a prolonged 
time. These cells might have been invaded by the bacilli at the time of initial 
infection, and have remained unnoticed by the immune system since then. 
Alternatively, bacteria from established foci might have escaped their confinement 
and infected more distantly located cells. Finally, it is possible that infected cells have 
migrated from infiltrates to healthy regions of the lung. To our knowledge, 
observations of host cells with a heavy bacterial burden in normal areas of the lung 
during mycobacterial infections have not been previously described.
10.5 In vivo expression of mycobacterial proteins in human 
lungs and lymph nodes
The investigation of protein-specific staining patterns in the lungs of mice infected 
with either BCG Pasteur or BCG Russia revealed only minor differences between the 
two strains. However, when we investigated expression of somatic and secreted 
proteins in human lung and lymph nodes infected with M. tuberculosis, we made 
several interesting observations. The secreted proteins were present at high levels in 
all granulomas in lungs, but the staining was markedly less frequent in granulomas in 
the lymph nodes. Here, these proteins were predominantly found in the necrotic 
centres, and less so in the granuloma cells. A well-structured granuloma is a correlate 
of effective immune responses that control the infection and limit bacterial growth. In 
the lungs, the granulomas had the appearance of disorganised infiltrates, they did not 
contain necrotic centres, and the bacillary load was high. Granulomas in the lymph 
nodes, however, had a well-organised granuloma structure with necrotic centres, and 
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seemed to more efficiently restrict bacillary multiplication. The latter explains why 
only low levels of secreted proteins were stained within these structures. The discrete 
stained spots in the necrotic centres might represent cells that contain multiplying 
bacilli that express higher amounts of secreted proteins, but that are gradually 
subjected to cell lysis and necrosis. Finding low levels of secreted proteins in well-
structured granulomas calls into question their importance as antigens during 
infection, and, by extension, if they should remain a primary focus in the 
development of diagnostic tools and vaccines. Proteins expressed in abundance 
during in vivo-infection are preferential targets of the cellular immune response, but if 
the expression is drastically reduced then so is the specific T-cell activation (276). 
Furthermore, evaluations of antibodies in sera from patients with tuberculosis suggest 
that mycobacterial surface proteins are more frequently recognised than secreted 
proteins (277,278). Studies in both humans and guinea pigs have revealed a lack of 
immune responses towards the secreted mycobacterial protein MPT53 (258), which 
also suggests that expression of secreted proteins is reduced during stable disease.
The situation may vary between secreted mycobacterial antigens. MPT64 was 
detected in all granulomas, and therefore seem to be retained within the granuloma 
cells, rather than being gradually cleared away. In our group, we previously showed 
that MPT64 was found more frequently in granulomas compared to non-
granulomatous inflammation, even if mycobacterial DNA was detected more 
frequently in the latter areas (279). In mice infected with M. tuberculosis, the 
bacillary load stabilises after an initial phase of multiplication. When the mice 
eventually become moribund, this is correlated to increased pathology rather than an 
increase in the bacterial burden (280). The change in pathology might be caused by 
the gradual accumulation of proteins such as MPT64, which at some point reach a 
threshold where they trigger exaggerated immune responses that in turn causes tissue 
damage.
The mycobacterial mce1 operon is associated with granuloma formation. Strains that 
are disrupted in this operon do not induce formation of organised granulomas, and 
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have been found to be more virulent than their wild type counterparts, in murine 
lungs (281). This is attributed to increase in pathology rather than bacillary load, 
which was similar between the strains. Our findings on one of the proteins in this 
operon, Mce1A, are in line with such studies. In the disorganised infiltrates in 
pulmonary lesions, Mce1A was detected less frequently compared to secreted 
proteins, and it was primarily cells surrounding the inflammatory infiltrates that 
stained positive for this protein. In contrast, Mce1A was found in all cases within 
organised granulomas in the lymph nodes, and the stain was predominantly found in 
cells of the granuloma, rather than necrotic centres. Both pathogen and host likely 
favour the formation of the granulomas during tuberculosis disease. For the host it 
constitutes a protective structure of bacillary containment. For the bacteria, the 
granuloma represents a stable structure in which it can survive for many years 
without causing fatal pathology to the host. The expression of Mce1A might therefore 
be a way for mycobacteria to induce formation of granulomas in the early stages of 
infection. However, for a long-term survival by way of infecting new individuals, the 
bacteria are eventually required to escape this enclosure. As mentioned above, it is 
perhaps the build-up of proteins like MPT64 that eventually facilitates the 
exaggerated immune response that cause destruction of tissue and release of bacilli 
into the bronchial tree.
It is a challenging task to study the in vivo expression of mycobacterial proteins, yet it 
is important and relevant for understanding how this organism can adapt to and 
influence the host responses during infection. What we know so far concerning the 
mycobacterial proteome is largely derived from studies of bacilli grown in culture. 
Some studies have attempted to alter the growth conditions to reflect the stimuli 
during infection in the host, for example by removing oxygen from the medium and 
thereby simulating conditions found in the caseum in the centre of the granuloma. 
However, such alterations only reflect certain aspects of the environment, and the 
conditions affecting the intracellular existence of the bacilli are far more complex in 
real life. The primary challenge for characterising mycobacterial proteins expressed 
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in vivo, is the influence of host proteins that by sheer number and quantity far 
outweighs proteins expressed by the bacilli. The modern technologies are not yet 
optimised and sensitive enough for unbiased analyses of such complex and target-rich 
samples. This holds true for both microarray-based and proteomic studies, although 
some recent attempts within both fields have been published. For example, 
transcriptome analyses have been performed on bacilli that have been isolated from 
the lungs of mice (282) and human tuberculosis patients (283), but the complexity of 
such models and the need to first isolate heterogeneous groups of bacilli from the 
source material, do not give us information about the specific context of protein 
expression. This also holds true for attempts to generate an in vivo proteomic profile. 
Kruh and colleagues performed proteomic analyses of lungs from infected guinea 
pigs, and were able to identify a little more than 500 mycobacterial proteins (284). 
Although promising, this is only one-fifth of what can be identified from bacteria 
grown in cultures (59). Identification of proteins by immunohistochemistry is limited 
by the antibodies available, expression can only be measured using semi-
quantification evaluation, and the method is quite laborious. However, it provides us 
with the opportunity to relate the specific protein expression to a particular context by 
correlating the staining pattern and relative staining intensity to features of the host 
pathology.
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11. Conclusions
The characterisation of the proteome and the dynamics of protein expression is key to 
understand how the mycobacterium succeeds so well in inhabiting its host. It has 
different means to enter host cells, and have several ways to evade their killing 
mechanisms. It seems to influence the formation of the granuloma to limit the extent 
of damage to the host, but it can also disrupt this structure to escape the boundaries of 
its host and infect new individuals. Secreted proteins, and proteins exposed on the 
surface of the bacilli, are the primary mycobacterial structures to interact with the 
host, and they become the most important immunogens during infection. It is 
therefore of utmost importance to understand when and where these proteins are 
expressed, and to identify their correct localisation. These are also key aspects when 
selecting candidates for vaccine- and drug development, and to find appropriate 
markers for diagnosing tuberculosis.
This work has investigated various aspects of mycobacterial protein expression and 
localisation, and the following conclusions can be drawn:
• The SignalP v3.0 hidden Markov model was found to the best performing 
algorithm for identifying signal peptide sequences and the respective cleavage 
site in mycobacterial proteins. This algorithm correctly identified the presence, 
or absence, of a signal peptide in the sequences of positive and negative 
validation sets, however, the cleavage site prediction can be improved. For 
characterisation of proteins secreted by the general secretory system in 
mycobacteria, this algorithm is currently the best option.
• Label-free quantitation identified proteins that were predicted to harbour a 
signal peptide, but which were found to be uncleaved and enriched in the 
membrane fraction. Components of the general secretory system are likely to 
target and integrate these proteins into the membrane, but for unknown reasons 
they are not processed by the signal peptidase. An inaccessible cleavage site, 
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and differences in signal peptide structure, can explain why some, but not all, 
cleavage sites were not processed. Another possible explanation is that amino 
acid substitutions in the -3 position in the AXA motif have a bigger penalty for 
mycobacterial proteins. The retained signal peptide might in itself function to 
retain the protein within the membrane fraction, and might influence both their 
function and structure.  
• The late BCG strain, BCG Pasteur, was more persistent and caused more 
pathology than the early strain, BCG Russia, in the lungs of C57BL/6 mice. 
This may be linked to an up-regulated expression of protective proteins such 
as antioxidants in BCG Pasteur. We confirmed the expression of both somatic 
and secreted proteins by immunohistochemistry, and the staining pattern was 
very similar between the two strains. Single cells with a high mycobacterial 
antigen load were detected in the normal lung parenchyma, which may reflect 
the potential of mycobacteria to modulate host killing responses and to limit 
their ability to signal other immune cells of the ongoing infection.
• The protein expression pattern in human lungs and lymphoid tissue infected 
with M. tuberculosis revealed differences seemingly related to the structural 
integrity of the granuloma. In the lungs, the granuloma was loosely formed 
and contained a high amount of secreted mycobacterial antigens. In contrast, 
the lymphoid tissue contained granulomas with a well-organised structure and 
necrotic centres, and few secreted proteins were found within host cells. The 
exception was MPT64, which were identified in all granulomas. Well-
structured granulomas are a correlate of protective immune responses, which 
could lead to a down-regulated expression of mycobacterial protein. In these 
regions, secreted proteins seemed to be rapidly degraded and/or transported 
away. In contrast, MPT64 appeared to accumulate, which might imply a role 
for this protein in persistence of infection. The mycobacterial protein Mce1A 
was found in all well-structured granulomas, and to a lesser extent in 
disorganised infiltrates. This is in line with other reports linking the mce-
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operon to granuloma formation, and it iterates a shared interest of the host and 
bacterium to limit the extent of pathology.
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